{
  "title": "Miastenia gravis en 2025",
  "guid": "5DE44BF95BA2F4442E407A7C",
  "filepath": "/sessions/bold-jolly-cerf/mnt/Dropbox/- Esquemas/- Entidades clínicas/Neurología/Miastenia ...-2025.smmx",
  "root": {
    "id": "0",
    "parent": "-1",
    "text": "Miastenia gravis en 2025",
    "guid": "aPH4k3ngqJ46PgD2Ia1GcQ",
    "children": [
      {
        "id": "1",
        "parent": "0",
        "text": "Cinco cosas nuevas",
        "guid": "BhxEHm7FW55DRz2bYA7jTw",
        "children": [
          {
            "id": "2",
            "parent": "1",
            "text": "Timectomía: el ensayo\nMGTX llega a su madurez",
            "guid": "",
            "children": [
              {
                "id": "3",
                "parent": "2",
                "text": "Eliminación del timo como\nfuente de autoinmunización",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "4",
            "parent": "1",
            "text": "Inmunoterapias",
            "guid": "",
            "children": []
          },
          {
            "id": "5",
            "parent": "1",
            "text": "Guías recientes",
            "guid": "",
            "children": []
          },
          {
            "id": "6",
            "parent": "1",
            "text": "Avances en\nbiomarcadores",
            "guid": "",
            "children": []
          },
          {
            "id": "7",
            "parent": "1",
            "text": "Concepto de \"edad\" y\n\"etapa\" de MG",
            "guid": "",
            "children": [
              {
                "id": "8",
                "parent": "7",
                "text": "Pacientes\npositivos para\nAChR",
                "guid": "",
                "children": []
              },
              {
                "id": "9",
                "parent": "7",
                "text": "Pacientes\npositivos para\nMuSK",
                "guid": "",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "10",
        "parent": "0",
        "text": "Cuatro esperanzas\npara el futuro",
        "guid": "",
        "children": [
          {
            "id": "11",
            "parent": "10",
            "text": "Mejoras en medicina\nde laboratorio",
            "guid": "",
            "children": [
              {
                "id": "12",
                "parent": "11",
                "text": "Diagnóstico rápido",
                "guid": "",
                "children": []
              },
              {
                "id": "13",
                "parent": "11",
                "text": "Estrategias efectivas para\nprotección neuromuscular",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "14",
            "parent": "10",
            "text": "Mayor investigación sobre respuesta al\ntratamiento en adultos mayores",
            "guid": "",
            "children": []
          },
          {
            "id": "15",
            "parent": "10",
            "text": "Mejor comprensión de\nla patofisiología",
            "guid": "",
            "children": []
          },
          {
            "id": "16",
            "parent": "10",
            "text": "Rol transformador de terapias\npara respuesta duradera",
            "guid": "",
            "children": [
              {
                "id": "17",
                "parent": "16",
                "text": "Células T CAR quiméricas",
                "guid": "",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "18",
        "parent": "0",
        "text": "# Miastenia gravis en\n2025 (continuación)",
        "guid": "GMrafUiNXsJXSOacNTEd9g",
        "children": []
      },
      {
        "id": "19",
        "parent": "0",
        "text": "Timectomía: el ensayo\nMGTX llega a su madurez",
        "guid": "",
        "children": [
          {
            "id": "20",
            "parent": "19",
            "text": "Ensayo\naleatorizado MGTX",
            "guid": "PMsiljWciNMLQhqfVR4HnA",
            "children": [
              {
                "id": "21",
                "parent": "20",
                "text": "Beneficio terapéutico en MG no timomatosa",
                "guid": "UsUPP18mIl17ufH-UXVGyg",
                "children": []
              },
              {
                "id": "22",
                "parent": "20",
                "text": "Rol fundamental del timo en inmunopatología",
                "guid": "CzKMZzCeFvxo8FjTf8xVMw",
                "children": []
              },
              {
                "id": "23",
                "parent": "20",
                "text": "Muestras histológicas",
                "guid": "",
                "children": [
                  {
                    "id": "24",
                    "parent": "23",
                    "text": "Hiperplasia folicular tímica",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "25",
                    "parent": "23",
                    "text": "Atrofia con elementos corticales en pacientes >50 años",
                    "guid": "DYhKiXpi5I9GlzQnSMEcXw",
                    "children": []
                  }
                ]
              },
              {
                "id": "26",
                "parent": "20",
                "text": "Resultados primarios",
                "guid": "",
                "children": [
                  {
                    "id": "27",
                    "parent": "26",
                    "text": "Puntuación QMG",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "28",
                    "parent": "26",
                    "text": "Requisito de prednisona durante 3 años",
                    "guid": "Kw2qIUXnP4F1aKBCfNFJPg",
                    "children": []
                  }
                ]
              },
              {
                "id": "29",
                "parent": "20",
                "text": "Grupo con timectomía\n+ prednisona",
                "guid": "ZE9JpE4sgntnHa4yNxRY4w",
                "children": [
                  {
                    "id": "30",
                    "parent": "29",
                    "text": "Puntuaciones QMG más bajas (5.47 vs 9.34)",
                    "guid": "PN92zRrgosUaz_6OCQh_LA",
                    "children": []
                  },
                  {
                    "id": "31",
                    "parent": "29",
                    "text": "Menor requisito de dosis (24 mg vs 48 mg)",
                    "guid": "INmxF3FQQBEMw2xcaqxBBw",
                    "children": []
                  }
                ]
              },
              {
                "id": "32",
                "parent": "20",
                "text": "Reducción media de 2.85\npuntos entre grupos",
                "guid": "",
                "children": [
                  {
                    "id": "33",
                    "parent": "32",
                    "text": "Superior al umbral clínicamente significativo\n(2. 3)",
                    "guid": "LVKk2GLXoDAIiZ-tOIUxQA",
                    "children": []
                  }
                ]
              },
              {
                "id": "34",
                "parent": "20",
                "text": "Estudio MGTX y\nextensión de dos años",
                "guid": "",
                "children": [
                  {
                    "id": "35",
                    "parent": "34",
                    "text": "Mayor tasa de estado de manifestación mínima (MMS)",
                    "guid": "E3W3LHF5-IE4UYZzUEDZwg",
                    "children": []
                  },
                  {
                    "id": "36",
                    "parent": "34",
                    "text": "Discontinuación de tratamiento con prednisona",
                    "guid": "JxaBVEOToRMlXuFeNJ7L3Q",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "37",
            "parent": "19",
            "text": "Consideraciones\nquirúrgicas",
            "guid": "",
            "children": [
              {
                "id": "38",
                "parent": "37",
                "text": "Crucial excepto cuando está contraindicada",
                "guid": "PfaFomv2FYZ9X-g8aQQvxA",
                "children": []
              },
              {
                "id": "39",
                "parent": "37",
                "text": "Técnicas mínimamente\ninvasivas",
                "guid": "Md1VB3LIiH9l1XkCbrzL1A",
                "children": [
                  {
                    "id": "40",
                    "parent": "39",
                    "text": "Timectomía toracoscópica asistida por video (VATS)",
                    "guid": "cfW3ogSIt1wZLx1iVkUBRg",
                    "children": []
                  },
                  {
                    "id": "41",
                    "parent": "39",
                    "text": "Cirugía toracoscópica asistida por robot (RATS)",
                    "guid": "DakrRACld5F3xUsALoLcWw",
                    "children": []
                  }
                ]
              },
              {
                "id": "42",
                "parent": "37",
                "text": "Beneficios perioperatorios",
                "guid": "",
                "children": [
                  {
                    "id": "43",
                    "parent": "42",
                    "text": "Menor pérdida de sangre",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "44",
                    "parent": "42",
                    "text": "Menor dolor",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "45",
                    "parent": "42",
                    "text": "Estancia hospitalaria más corta",
                    "guid": "UrU51wBMy5QNWVopAAferw",
                    "children": []
                  }
                ]
              },
              {
                "id": "46",
                "parent": "37",
                "text": "Elección de técnica",
                "guid": "",
                "children": [
                  {
                    "id": "47",
                    "parent": "46",
                    "text": "Determinada por disponibilidad regional",
                    "guid": "YyRrxBXi-dY4jQ_vdpoi8A",
                    "children": []
                  },
                  {
                    "id": "48",
                    "parent": "46",
                    "text": "Preferencia del cirujano",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "49",
                    "parent": "46",
                    "text": "Escasez de ensayos aleatorizados",
                    "guid": "B1zyV3DelmNG2vyzLnNzqw",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "50",
            "parent": "19",
            "text": "Investigación en curso",
            "guid": "",
            "children": [
              {
                "id": "51",
                "parent": "50",
                "text": "Diferencias histológicas para estratificación de pacientes",
                "guid": "NHI3dmw53hFjEj-Icmi9GA",
                "children": []
              },
              {
                "id": "52",
                "parent": "50",
                "text": "Análisis digital de\nmuestras tímicas",
                "guid": "",
                "children": [
                  {
                    "id": "53",
                    "parent": "52",
                    "text": "Correlación entre centros\ngerminales ectópicos y mejoría",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "54",
                "parent": "50",
                "text": "Limitaciones de imágenes\nconvencionales",
                "guid": "UzqwREFCZd94yhRyYOPbiA",
                "children": [
                  {
                    "id": "55",
                    "parent": "54",
                    "text": "Baja sensibilidad de MRI torácica (28.6%)",
                    "guid": "WC_zl2ByJ8VbbOzcCg1Ing",
                    "children": []
                  },
                  {
                    "id": "56",
                    "parent": "54",
                    "text": "Mayor sensibilidad de PET/CT (58.6%)",
                    "guid": "QefdcHCPX3IPZrfjM92VEg",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "id": "57",
        "parent": "0",
        "text": "Pacientes sin anticuerpos\nAChR detectables",
        "guid": "",
        "children": [
          {
            "id": "58",
            "parent": "57",
            "text": "15% de pacientes con MG",
            "guid": "",
            "children": []
          },
          {
            "id": "59",
            "parent": "57",
            "text": "Subgrupos con\nautoinmunoreactividad",
            "guid": "",
            "children": [
              {
                "id": "60",
                "parent": "59",
                "text": "Proteína quinasa específica de músculo (MuSK)",
                "guid": "dRgWziiV1UYKIpZYR81QpQ",
                "children": []
              },
              {
                "id": "61",
                "parent": "59",
                "text": "Proteína 4 relacionada con receptor de lipoproteína de baja densidad (LRP4)",
                "guid": "KOKg2hd78IFH1S9VDAcMnw",
                "children": []
              }
            ]
          },
          {
            "id": "62",
            "parent": "57",
            "text": "Evidencia limitada sobre eficacia de timectomía",
            "guid": "LV7qVwBiP0QCoS-PNLvcrw",
            "children": []
          },
          {
            "id": "63",
            "parent": "57",
            "text": "Observaciones",
            "guid": "",
            "children": [
              {
                "id": "64",
                "parent": "63",
                "text": "Beneficio terapéutico en proporción de pacientes juveniles",
                "guid": "cUDVp0l8LEJjL1BaJbMNHQ",
                "children": []
              },
              {
                "id": "65",
                "parent": "63",
                "text": "Incertidumbre sobre beneficios sostenidos",
                "guid": "NbYKVEZBj-MYG8o2DeX96w",
                "children": []
              }
            ]
          },
          {
            "id": "66",
            "parent": "57",
            "text": "Timectomía en MG ocular",
            "guid": "",
            "children": [
              {
                "id": "67",
                "parent": "66",
                "text": "Solo indicada cuando fallan agentes farmacológicos",
                "guid": "JrO3qHOItxIX80aKee5n7A",
                "children": []
              },
              {
                "id": "68",
                "parent": "66",
                "text": "Contraindicaciones absolutas",
                "guid": "NMsc8RC9Wvxa0kN0drL6YQ",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "69",
        "parent": "0",
        "text": "Panorama expandido de\ntratamiento en miastenia gravis",
        "guid": "",
        "children": [
          {
            "id": "70",
            "parent": "69",
            "text": "Objetivos del tratamiento",
            "guid": "",
            "children": [
              {
                "id": "71",
                "parent": "70",
                "text": "Proteger la unión\nneuromuscular",
                "guid": "",
                "children": []
              },
              {
                "id": "72",
                "parent": "70",
                "text": "Eliminar células efectoras productoras\nde anticuerpos patogénicos",
                "guid": "",
                "children": []
              },
              {
                "id": "73",
                "parent": "70",
                "text": "Reducir anticuerpos\nen circulación",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "74",
            "parent": "69",
            "text": "Tratamientos disponibles\n(revisión previa)",
            "guid": "",
            "children": [
              {
                "id": "75",
                "parent": "74",
                "text": "Categorización en\nprimeros dos grupos",
                "guid": "",
                "children": []
              },
              {
                "id": "76",
                "parent": "74",
                "text": "Opciones\ninmunosupresoras\nhistóricas",
                "guid": "",
                "children": [
                  {
                    "id": "77",
                    "parent": "76",
                    "text": "Corticosteroides\ny azatioprina",
                    "guid": "",
                    "children": [
                      {
                        "id": "78",
                        "parent": "77",
                        "text": "Efectos\nsecundarios\nnotables",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "79",
                        "parent": "77",
                        "text": "Pulsaciones frecuentes\ne inconvenientes",
                        "guid": "",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "80",
                    "parent": "76",
                    "text": "Inmunoglobulina\nintravenosa (IVIG)",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "81",
                    "parent": "76",
                    "text": "Intercambio de plasma",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "82",
                    "parent": "76",
                    "text": "Control insuficiente en\nhasta 15% de casos",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "83",
            "parent": "69",
            "text": "Avances recientes",
            "guid": "",
            "children": [
              {
                "id": "84",
                "parent": "83",
                "text": "Timectomía para MG\npositiva a AChR",
                "guid": "",
                "children": [
                  {
                    "id": "85",
                    "parent": "84",
                    "text": "Aborda la cascada de\nenfermedad en origen",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "86",
                    "parent": "84",
                    "text": "Centros germinales tímicos\nfomentan células plasmáticas\nproductoras de anticuerpos",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "87",
                "parent": "83",
                "text": "Expansión de\nterapias\nmodificadoras",
                "guid": "",
                "children": [
                  {
                    "id": "88",
                    "parent": "87",
                    "text": "Varios ensayos\nclínicos completados",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "89",
                    "parent": "87",
                    "text": "Nuevos agentes disponibles\ndesde revisión anterior",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "id": "90",
        "parent": "0",
        "text": "# Miastenia gravis en\n2025 (continuación)",
        "guid": "Ftv8oAwl2WsLP5G2Y6sEhA",
        "children": []
      },
      {
        "id": "91",
        "parent": "0",
        "text": "Resumen del linaje\nde células B",
        "guid": "",
        "children": [
          {
            "id": "92",
            "parent": "91",
            "text": "Diferenciación y fenotipos de superficie celular",
            "guid": "AUy6b2o4-1cqkI9zdmTRPQ",
            "children": [
              {
                "id": "93",
                "parent": "92",
                "text": "Médula ósea",
                "guid": "Es7QnTSzJcs-MiHjO7FxeA",
                "children": [
                  {
                    "id": "94",
                    "parent": "93",
                    "text": "Células B inmaduras",
                    "guid": "",
                    "children": [
                      {
                        "id": "95",
                        "parent": "94",
                        "text": "CD19+",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "96",
                        "parent": "94",
                        "text": "CD20+",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "97",
                        "parent": "94",
                        "text": "CD27-",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "98",
                        "parent": "94",
                        "text": "IgM+",
                        "guid": "",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "id": "99",
                "parent": "92",
                "text": "Periferia",
                "guid": "TC8WTAYHUThHuH4XeY4ApA",
                "children": [
                  {
                    "id": "100",
                    "parent": "99",
                    "text": "Células B ingenuas",
                    "guid": "",
                    "children": [
                      {
                        "id": "101",
                        "parent": "100",
                        "text": "CD19+",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "102",
                        "parent": "100",
                        "text": "CD20+",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "103",
                        "parent": "100",
                        "text": "CD27-",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "104",
                        "parent": "100",
                        "text": "IgD+",
                        "guid": "",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "id": "105",
                "parent": "92",
                "text": "Centro germinal",
                "guid": "BmmQfEpZraYuSd1Td6pmJA",
                "children": [
                  {
                    "id": "106",
                    "parent": "105",
                    "text": "Encuentro con antígeno",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "107",
                    "parent": "105",
                    "text": "Célula B activada",
                    "guid": "",
                    "children": [
                      {
                        "id": "108",
                        "parent": "107",
                        "text": "CD40",
                        "guid": "",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "109",
                    "parent": "105",
                    "text": "Célula T auxiliadora",
                    "guid": "",
                    "children": [
                      {
                        "id": "110",
                        "parent": "109",
                        "text": "CD40L",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "111",
                        "parent": "109",
                        "text": "IL-2",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "112",
                        "parent": "109",
                        "text": "IL-21",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "113",
                        "parent": "109",
                        "text": "TNF-α",
                        "guid": "",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "114",
                    "parent": "105",
                    "text": "Memoria B no conmutada",
                    "guid": "",
                    "children": [
                      {
                        "id": "115",
                        "parent": "114",
                        "text": "CD19+",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "116",
                        "parent": "114",
                        "text": "CD20+",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "117",
                        "parent": "114",
                        "text": "CD27+",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "118",
                        "parent": "114",
                        "text": "IgD+",
                        "guid": "",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "119",
                    "parent": "105",
                    "text": "Memoria B conmutada",
                    "guid": "",
                    "children": [
                      {
                        "id": "120",
                        "parent": "119",
                        "text": "CD19+",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "121",
                        "parent": "119",
                        "text": "CD20+",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "122",
                        "parent": "119",
                        "text": "CD27+",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "123",
                        "parent": "119",
                        "text": "IgD-/IgG+",
                        "guid": "",
                        "children": []
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "id": "124",
            "parent": "91",
            "text": "Nicho de células\nplasmáticas",
            "guid": "",
            "children": [
              {
                "id": "125",
                "parent": "124",
                "text": "Plasmablasto",
                "guid": "",
                "children": [
                  {
                    "id": "126",
                    "parent": "125",
                    "text": "CD19+",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "127",
                    "parent": "125",
                    "text": "CD20bajo",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "128",
                    "parent": "125",
                    "text": "CD27+",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "129",
                    "parent": "125",
                    "text": "CD38++",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "130",
                    "parent": "125",
                    "text": "CD138-",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "131",
                "parent": "124",
                "text": "Células plasmáticas\nde corta vida",
                "guid": "",
                "children": [
                  {
                    "id": "132",
                    "parent": "131",
                    "text": "CD19+",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "133",
                    "parent": "131",
                    "text": "CD20-",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "134",
                    "parent": "131",
                    "text": "CD27+",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "135",
                    "parent": "131",
                    "text": "CD38++",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "136",
                    "parent": "131",
                    "text": "CD138++",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "137",
                "parent": "124",
                "text": "Células plasmáticas\nde larga vida",
                "guid": "",
                "children": [
                  {
                    "id": "138",
                    "parent": "137",
                    "text": "CD19+",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "139",
                    "parent": "137",
                    "text": "CD20-",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "140",
                    "parent": "137",
                    "text": "CD27+",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "141",
                    "parent": "137",
                    "text": "CD38++",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "142",
                    "parent": "137",
                    "text": "CD138+",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "id": "143",
        "parent": "0",
        "text": "Protección de la unión neuromuscular en\nMG con anticuerpos AChR",
        "guid": "",
        "children": [
          {
            "id": "144",
            "parent": "143",
            "text": "Anticuerpos IgG1\nde AChR-MG",
            "guid": "",
            "children": [
              {
                "id": "145",
                "parent": "144",
                "text": "Activación del complemento",
                "guid": "E9XZ6RF5La0dXXNBSYvkPQ",
                "children": []
              },
              {
                "id": "146",
                "parent": "144",
                "text": "Daño tisular en membrana postsináptica",
                "guid": "V7q9kDV5PXdXceIofm51OA",
                "children": []
              }
            ]
          },
          {
            "id": "147",
            "parent": "143",
            "text": "Eculizumab",
            "guid": "",
            "children": [
              {
                "id": "148",
                "parent": "147",
                "text": "Anticuerpo monoclonal (mAb)",
                "guid": "KQH0im9lKLJ4XN0kXc0Rew",
                "children": []
              },
              {
                "id": "149",
                "parent": "147",
                "text": "Inhibe componente C5 de la cascada del complemento",
                "guid": "ACKDr1MvIJhUgAvdAW8-Hg",
                "children": []
              },
              {
                "id": "150",
                "parent": "147",
                "text": "Ensayo fase 3\n(REGAIN) en 2017",
                "guid": "",
                "children": [
                  {
                    "id": "151",
                    "parent": "150",
                    "text": "125 pacientes\npositivos para AChR",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "152",
                    "parent": "150",
                    "text": "62 asignados a\nEculizumab",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "153",
                    "parent": "150",
                    "text": "63 a placebo",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "154",
                    "parent": "150",
                    "text": "Pacientes adultos (≥18 años) con\nenfermedad refractaria",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "155",
                    "parent": "150",
                    "text": "Tratamiento previo con\ninmunoterapia estándar ≥12\nmeses",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "156",
                    "parent": "150",
                    "text": "Sin control de síntomas",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "157",
                "parent": "147",
                "text": "Resultados",
                "guid": "",
                "children": [
                  {
                    "id": "158",
                    "parent": "157",
                    "text": "No alcanzó punto final primario\n(cambio en escala MG-ADL)",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "159",
                    "parent": "157",
                    "text": "Puntos finales\nsecundarios\nfavorables",
                    "guid": "",
                    "children": [
                      {
                        "id": "160",
                        "parent": "159",
                        "text": "Puntuación compuesta de\nmiastenia gravis (MGC)",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "161",
                        "parent": "159",
                        "text": "QMG",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "162",
                        "parent": "159",
                        "text": "MG Quality-of-Life\n15 (MG-QoL15)",
                        "guid": "",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "163",
                    "parent": "157",
                    "text": "Fase de extensión abierta",
                    "guid": "",
                    "children": [
                      {
                        "id": "164",
                        "parent": "163",
                        "text": "Mejora sostenida a\n130 semanas",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "165",
                        "parent": "163",
                        "text": "88% alcanzaron estado\n\"mejorado\" según MGFA",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "166",
                        "parent": "163",
                        "text": "57.3% con\n\"manifestación\nmínima\"",
                        "guid": "",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "167",
                    "parent": "157",
                    "text": "Aprobación",
                    "guid": "",
                    "children": [
                      {
                        "id": "168",
                        "parent": "167",
                        "text": "FDA y EMA en 2017 para MG\npositiva para AChR",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "169",
                        "parent": "167",
                        "text": "Dos inhibidores C5\nadicionales disponibles",
                        "guid": "",
                        "children": []
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "id": "170",
        "parent": "0",
        "text": "# Miastenia gravis en\n2025 (continuación)",
        "guid": "WSZHhmNNECBBifuiDdbezg",
        "children": []
      },
      {
        "id": "171",
        "parent": "0",
        "text": "Tabla 1: Terapias autorizadas y\nen investigación que modifican la\nenfermedad en MG",
        "guid": "",
        "children": []
      },
      {
        "id": "172",
        "parent": "0",
        "text": "Categoría: Protección por\ninhibición del complemento",
        "guid": "",
        "children": [
          {
            "id": "173",
            "parent": "172",
            "text": "Eculizumab",
            "guid": "",
            "children": [
              {
                "id": "174",
                "parent": "173",
                "text": "Aprobación",
                "guid": "",
                "children": [
                  {
                    "id": "175",
                    "parent": "174",
                    "text": "FDA (2017)",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "176",
                    "parent": "174",
                    "text": "EMA (2017)",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "177",
                "parent": "173",
                "text": "Indicación",
                "guid": "",
                "children": [
                  {
                    "id": "178",
                    "parent": "177",
                    "text": "AChR Ab+ MG\nadultos refractarios",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "179",
                "parent": "173",
                "text": "Descripción",
                "guid": "",
                "children": [
                  {
                    "id": "180",
                    "parent": "179",
                    "text": "IgG2/4 kappa humanizada\ncontra C5 humana",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "181",
                "parent": "173",
                "text": "Mecanismo de acción",
                "guid": "",
                "children": [
                  {
                    "id": "182",
                    "parent": "181",
                    "text": "Bloquea C5, escisión\ny complemento",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "183",
            "parent": "172",
            "text": "Ravulizumab",
            "guid": "",
            "children": [
              {
                "id": "184",
                "parent": "183",
                "text": "Aprobación",
                "guid": "",
                "children": [
                  {
                    "id": "185",
                    "parent": "184",
                    "text": "FDA (2022)",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "186",
                    "parent": "184",
                    "text": "EMA (2022)",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "187",
                "parent": "183",
                "text": "Indicación",
                "guid": "",
                "children": [
                  {
                    "id": "188",
                    "parent": "187",
                    "text": "AChR Ab+ MG adultos\n(en terapia EU)",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "189",
                "parent": "183",
                "text": "Descripción",
                "guid": "",
                "children": [
                  {
                    "id": "190",
                    "parent": "189",
                    "text": "Humanizada IgG4 mAb",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "191",
                "parent": "183",
                "text": "Mecanismo de acción",
                "guid": "",
                "children": [
                  {
                    "id": "192",
                    "parent": "191",
                    "text": "Bloquea C5, escisión\ny complemento",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "193",
            "parent": "172",
            "text": "Zilucoplan",
            "guid": "",
            "children": [
              {
                "id": "194",
                "parent": "193",
                "text": "Aprobación",
                "guid": "",
                "children": [
                  {
                    "id": "195",
                    "parent": "194",
                    "text": "FDA (2023)",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "196",
                "parent": "193",
                "text": "Indicación",
                "guid": "",
                "children": [
                  {
                    "id": "197",
                    "parent": "196",
                    "text": "AChR Ab+ MG adultos",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "198",
                "parent": "193",
                "text": "Descripción",
                "guid": "",
                "children": [
                  {
                    "id": "199",
                    "parent": "198",
                    "text": "Pequeño C5, C5a, incluyendo\npéptidos macrocíclicos",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "200",
                "parent": "193",
                "text": "Mecanismo de acción",
                "guid": "",
                "children": [
                  {
                    "id": "201",
                    "parent": "200",
                    "text": "Bloquea C5,\nescisión/complemento",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "202",
            "parent": "172",
            "text": "Cetirizumab",
            "guid": "",
            "children": [
              {
                "id": "203",
                "parent": "202",
                "text": "Aprobación",
                "guid": "",
                "children": [
                  {
                    "id": "204",
                    "parent": "203",
                    "text": "Fase 3 (NCT05556996)",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "205",
                "parent": "202",
                "text": "Indicación",
                "guid": "",
                "children": [
                  {
                    "id": "206",
                    "parent": "205",
                    "text": "AChR Ab+ MG adultos",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "207",
                "parent": "202",
                "text": "Descripción",
                "guid": "",
                "children": [
                  {
                    "id": "208",
                    "parent": "207",
                    "text": "Anticuerpo IgG1\nhumanizado contra C5",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "209",
                "parent": "202",
                "text": "Mecanismo de acción",
                "guid": "",
                "children": [
                  {
                    "id": "210",
                    "parent": "209",
                    "text": "Bloquea C5, escisión\ny complemento",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "211",
            "parent": "172",
            "text": "Pozelimab + Cemdisiran",
            "guid": "",
            "children": [
              {
                "id": "212",
                "parent": "211",
                "text": "Aprobación",
                "guid": "",
                "children": [
                  {
                    "id": "213",
                    "parent": "212",
                    "text": "Fase 3 (NCT05070858)",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "214",
                "parent": "211",
                "text": "Indicación",
                "guid": "",
                "children": [
                  {
                    "id": "215",
                    "parent": "214",
                    "text": "AChR, LEMS Ab+\nMG adultos",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "216",
                "parent": "211",
                "text": "Descripción",
                "guid": "",
                "children": [
                  {
                    "id": "217",
                    "parent": "216",
                    "text": "Anticuerpo IgG4 humanizado contra C5 y\nsilenciamiento génico para C5",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "218",
                "parent": "211",
                "text": "Mecanismo de acción",
                "guid": "",
                "children": [
                  {
                    "id": "219",
                    "parent": "218",
                    "text": "Bloquea C5, escisión/complemento y\nsilenciamiento de ARNm de C5",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "id": "220",
        "parent": "0",
        "text": "Categoría: Efectos\nsobre anticuerpos",
        "guid": "",
        "children": [
          {
            "id": "221",
            "parent": "220",
            "text": "Efgartigimod",
            "guid": "",
            "children": [
              {
                "id": "222",
                "parent": "221",
                "text": "Aprobación",
                "guid": "",
                "children": [
                  {
                    "id": "223",
                    "parent": "222",
                    "text": "FDA (2021)",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "224",
                    "parent": "222",
                    "text": "EMA (2022)",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "225",
                "parent": "221",
                "text": "Indicación",
                "guid": "",
                "children": [
                  {
                    "id": "226",
                    "parent": "225",
                    "text": "AChR Ab+ MG adultos\n(en terapia EU)",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "227",
                "parent": "221",
                "text": "Descripción",
                "guid": "",
                "children": [
                  {
                    "id": "228",
                    "parent": "227",
                    "text": "IgG1 Fc-fragmento\nhumano a FcRN",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "229",
                "parent": "221",
                "text": "Mecanismo de acción",
                "guid": "",
                "children": [
                  {
                    "id": "230",
                    "parent": "229",
                    "text": "Inhibe endogenous IgG reciclaje vía\ncompetencia FcRN bloqueo",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "231",
            "parent": "220",
            "text": "Rozanolixizumab",
            "guid": "",
            "children": [
              {
                "id": "232",
                "parent": "231",
                "text": "Aprobación",
                "guid": "",
                "children": [
                  {
                    "id": "233",
                    "parent": "232",
                    "text": "FDA (2023)",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "234",
                    "parent": "232",
                    "text": "EMA (2023)",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "235",
                "parent": "231",
                "text": "Indicación",
                "guid": "",
                "children": [
                  {
                    "id": "236",
                    "parent": "235",
                    "text": "AChR and MuSK Ab+\nMG pacientes",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "237",
                "parent": "231",
                "text": "Descripción",
                "guid": "",
                "children": [
                  {
                    "id": "238",
                    "parent": "237",
                    "text": "Humanizado IgG4\nmAb a FcRN",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "239",
                "parent": "231",
                "text": "Mecanismo de acción",
                "guid": "",
                "children": [
                  {
                    "id": "240",
                    "parent": "239",
                    "text": "Inhibe endogenous IgG reciclaje vía\ncompetencia FcRN bloqueo",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "241",
            "parent": "220",
            "text": "Nipocalimab",
            "guid": "",
            "children": [
              {
                "id": "242",
                "parent": "241",
                "text": "Aprobación",
                "guid": "",
                "children": [
                  {
                    "id": "243",
                    "parent": "242",
                    "text": "Fase 3 (NCT05052632)",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "244",
                "parent": "241",
                "text": "Indicación",
                "guid": "",
                "children": [
                  {
                    "id": "245",
                    "parent": "244",
                    "text": "MG adultos\n(cualquiera 2-18\naños)",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "246",
                "parent": "241",
                "text": "Descripción",
                "guid": "",
                "children": [
                  {
                    "id": "247",
                    "parent": "246",
                    "text": "Anticuerpo IgG1\nhumano contra FcRN",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "248",
                "parent": "241",
                "text": "Mecanismo de acción",
                "guid": "",
                "children": [
                  {
                    "id": "249",
                    "parent": "248",
                    "text": "Inhibe endogenous IgG reciclaje vía\ncompetencia FcRN bloqueo",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "250",
            "parent": "220",
            "text": "Batoclimab",
            "guid": "",
            "children": [
              {
                "id": "251",
                "parent": "250",
                "text": "Aprobación",
                "guid": "",
                "children": [
                  {
                    "id": "252",
                    "parent": "251",
                    "text": "Fase 3 (NCT04838184)",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "253",
                "parent": "250",
                "text": "Indicación",
                "guid": "",
                "children": [
                  {
                    "id": "254",
                    "parent": "253",
                    "text": "MG adultos",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "255",
                "parent": "250",
                "text": "Descripción",
                "guid": "",
                "children": [
                  {
                    "id": "256",
                    "parent": "255",
                    "text": "Anticuerpo IgG1\nhumano contra FcRN",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "257",
                "parent": "250",
                "text": "Mecanismo de acción",
                "guid": "",
                "children": [
                  {
                    "id": "258",
                    "parent": "257",
                    "text": "Inhibe endogenous IgG reciclaje vía\ncompetencia FcRN bloqueo",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "id": "259",
        "parent": "0",
        "text": "Categoría: Efectos\nsobre células B",
        "guid": "",
        "children": [
          {
            "id": "260",
            "parent": "259",
            "text": "Rituximab",
            "guid": "",
            "children": [
              {
                "id": "261",
                "parent": "260",
                "text": "Aprobación",
                "guid": "",
                "children": [
                  {
                    "id": "262",
                    "parent": "261",
                    "text": "No dirigido, uso fuera de\nindicación aprobado por NICE",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "263",
                "parent": "260",
                "text": "Indicación",
                "guid": "",
                "children": [
                  {
                    "id": "264",
                    "parent": "263",
                    "text": "MG específica, MuSK Ab+",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "265",
                "parent": "260",
                "text": "Descripción",
                "guid": "",
                "children": [
                  {
                    "id": "266",
                    "parent": "265",
                    "text": "Anticuerpo Quimérico\nhumano anti-CD20",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "267",
                "parent": "260",
                "text": "Mecanismo de acción",
                "guid": "",
                "children": [
                  {
                    "id": "268",
                    "parent": "267",
                    "text": "Depleta rango\nde células B",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "269",
            "parent": "259",
            "text": "Inebilizumab",
            "guid": "",
            "children": [
              {
                "id": "270",
                "parent": "269",
                "text": "Aprobación",
                "guid": "",
                "children": [
                  {
                    "id": "271",
                    "parent": "270",
                    "text": "Fase 3 (NCT04524273)",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "272",
                "parent": "269",
                "text": "Indicación",
                "guid": "",
                "children": [
                  {
                    "id": "273",
                    "parent": "272",
                    "text": "AChR+ MuSK+\nGMG adultos",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "274",
                "parent": "269",
                "text": "Descripción",
                "guid": "",
                "children": [
                  {
                    "id": "275",
                    "parent": "274",
                    "text": "Humanizado IgG1\nanti-CD19 mAb",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "276",
                "parent": "269",
                "text": "Mecanismo de acción",
                "guid": "",
                "children": [
                  {
                    "id": "277",
                    "parent": "276",
                    "text": "Depleta rango B cells con\npoblación específica",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "id": "278",
        "parent": "0",
        "text": "Categoría: Efectos sobre\ncélulas B, células T y BAFF",
        "guid": "",
        "children": [
          {
            "id": "279",
            "parent": "278",
            "text": "Belimucept",
            "guid": "",
            "children": [
              {
                "id": "280",
                "parent": "279",
                "text": "Aprobación",
                "guid": "",
                "children": [
                  {
                    "id": "281",
                    "parent": "280",
                    "text": "Fase 3 (NCT05371690)",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "282",
                "parent": "279",
                "text": "Indicación",
                "guid": "",
                "children": [
                  {
                    "id": "283",
                    "parent": "282",
                    "text": "gMG adultos 18-80",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "284",
                "parent": "279",
                "text": "Descripción",
                "guid": "",
                "children": [
                  {
                    "id": "285",
                    "parent": "284",
                    "text": "Proteína de fusión formada de dominio\nCTLA-4 humano IgG Fc receptor",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "286",
                "parent": "279",
                "text": "Mecanismo de acción",
                "guid": "",
                "children": [
                  {
                    "id": "287",
                    "parent": "286",
                    "text": "Inhibe células B de\nactivación APRIL y BAFF",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "288",
            "parent": "278",
            "text": "Satralizumab",
            "guid": "",
            "children": [
              {
                "id": "289",
                "parent": "288",
                "text": "Aprobación",
                "guid": "",
                "children": [
                  {
                    "id": "290",
                    "parent": "289",
                    "text": "Fase 3 (NCT05082570)",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "291",
                "parent": "288",
                "text": "Indicación",
                "guid": "",
                "children": [
                  {
                    "id": "292",
                    "parent": "291",
                    "text": "Seropositive MG 12+ años",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "293",
                "parent": "288",
                "text": "Descripción",
                "guid": "",
                "children": [
                  {
                    "id": "294",
                    "parent": "293",
                    "text": "Humanizado mAb a soluble e IL-6\ntransmembranario receptor",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "295",
                "parent": "288",
                "text": "Mecanismo de acción",
                "guid": "",
                "children": [
                  {
                    "id": "296",
                    "parent": "295",
                    "text": "Bloquea IL-6 señalización y\nactivación de células especificas",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "id": "297",
        "parent": "0",
        "text": "Categoría:\nCélulas CAR T",
        "guid": "",
        "children": [
          {
            "id": "298",
            "parent": "297",
            "text": "Células CAR T",
            "guid": "",
            "children": [
              {
                "id": "299",
                "parent": "298",
                "text": "Aprobación",
                "guid": "",
                "children": [
                  {
                    "id": "300",
                    "parent": "299",
                    "text": "Fase 1 (estudio piloto)",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "301",
                "parent": "298",
                "text": "Indicación",
                "guid": "",
                "children": [
                  {
                    "id": "302",
                    "parent": "301",
                    "text": "Adulto MG 18+",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "303",
                "parent": "298",
                "text": "Descripción",
                "guid": "",
                "children": [
                  {
                    "id": "304",
                    "parent": "303",
                    "text": "Células T con receptor antígeno\nquimérico contra receptor Bcl",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "305",
                "parent": "298",
                "text": "Mecanismo de acción",
                "guid": "",
                "children": [
                  {
                    "id": "306",
                    "parent": "305",
                    "text": "Depleción de poblaciones\ncelulares específicas involucradas\nen inmunopatología de MG",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "id": "307",
        "parent": "0",
        "text": "Categoría:\nCélulas CAR T",
        "guid": "",
        "children": [
          {
            "id": "308",
            "parent": "307",
            "text": "Células CAR T",
            "guid": "",
            "children": [
              {
                "id": "309",
                "parent": "308",
                "text": "Aprobación",
                "guid": "",
                "children": [
                  {
                    "id": "310",
                    "parent": "309",
                    "text": "Fase 1 (NCT05612)",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "311",
                "parent": "308",
                "text": "Indicación",
                "guid": "",
                "children": [
                  {
                    "id": "312",
                    "parent": "311",
                    "text": "Adulto MuSK positivo 18+",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "313",
                "parent": "308",
                "text": "Descripción",
                "guid": "",
                "children": [
                  {
                    "id": "314",
                    "parent": "313",
                    "text": "Células T CAR ingeniería\ncontra MuSK antígeno",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "315",
                "parent": "308",
                "text": "Mecanismo de acción",
                "guid": "",
                "children": [
                  {
                    "id": "316",
                    "parent": "315",
                    "text": "Depleción de células B\nMuSK-específicas",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "id": "317",
        "parent": "0",
        "text": "Categoría: Extracción de timo\no inmunomodulador",
        "guid": "",
        "children": [
          {
            "id": "318",
            "parent": "317",
            "text": "Timectomía",
            "guid": "",
            "children": [
              {
                "id": "319",
                "parent": "318",
                "text": "Aprobación",
                "guid": "",
                "children": [
                  {
                    "id": "320",
                    "parent": "319",
                    "text": "Estudio caso-control\n(NCT04453661)",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "321",
                "parent": "318",
                "text": "Indicación",
                "guid": "",
                "children": [
                  {
                    "id": "322",
                    "parent": "321",
                    "text": "Todos adultos 18+ con MG",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "323",
                "parent": "318",
                "text": "Descripción",
                "guid": "",
                "children": [
                  {
                    "id": "324",
                    "parent": "323",
                    "text": "Extirpación mínimamente\ninvasiva del timo",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "325",
                "parent": "318",
                "text": "Mecanismo de acción",
                "guid": "",
                "children": [
                  {
                    "id": "326",
                    "parent": "325",
                    "text": "Eliminación de timo como sitio de\nproducción de autoanticuerpos y\nzona de inmunización",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "id": "327",
        "parent": "0",
        "text": "# Miastenia gravis en\n2025 (continuación)",
        "guid": "cW6yDCEY2Yt3qCvyeNB-nw",
        "children": []
      },
      {
        "id": "328",
        "parent": "0",
        "text": "Avances en tratamiento en MG positiva\npara anticuerpos de quinasa específica\nde músculo (MuSK-Ab)",
        "guid": "",
        "children": [
          {
            "id": "329",
            "parent": "328",
            "text": "Panel A: Cronología de nuevos\ntratamientos disponibles desde 2016",
            "guid": "",
            "children": [
              {
                "id": "330",
                "parent": "329",
                "text": "Yan et al -\nBatoclimab\n(2024)",
                "guid": "",
                "children": [
                  {
                    "id": "331",
                    "parent": "330",
                    "text": "5 pacientes MuSK",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "332",
                    "parent": "330",
                    "text": "2 doble positivos",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "333",
                "parent": "329",
                "text": "Rozanolixizumab -\nMycarinG (2023)",
                "guid": "",
                "children": [
                  {
                    "id": "334",
                    "parent": "333",
                    "text": "21 pacientes MuSK",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "335",
                "parent": "329",
                "text": "Hehir et al -\nRituximab (2017)",
                "guid": "",
                "children": [
                  {
                    "id": "336",
                    "parent": "335",
                    "text": "55 pacientes MuSK",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "337",
                "parent": "329",
                "text": "ADAPT -\nEfgartigimod\n(2017)",
                "guid": "",
                "children": [
                  {
                    "id": "338",
                    "parent": "337",
                    "text": "6 pacientes MuSK",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "339",
                "parent": "329",
                "text": "Tratamientos\nestablecidos 2016",
                "guid": "",
                "children": [
                  {
                    "id": "340",
                    "parent": "339",
                    "text": "Prednisona",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "341",
                    "parent": "339",
                    "text": "Corticosteroides",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "342",
                    "parent": "339",
                    "text": "Azatioprina",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "343",
                    "parent": "339",
                    "text": "Intercambio de plasma",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "344",
                    "parent": "339",
                    "text": "IVIG",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "345",
            "parent": "328",
            "text": "Panel B: Timo normal en MuSK MG\n(timectomía no indicada)",
            "guid": "",
            "children": [
              {
                "id": "346",
                "parent": "345",
                "text": "Patología tímica",
                "guid": "",
                "children": [
                  {
                    "id": "347",
                    "parent": "346",
                    "text": "Control vs AChR vs MuSK",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "348",
                "parent": "345",
                "text": "Métodos de\ntinción modernos",
                "guid": "",
                "children": []
              },
              {
                "id": "349",
                "parent": "345",
                "text": "Inmunofluorescencia",
                "guid": "",
                "children": [
                  {
                    "id": "350",
                    "parent": "349",
                    "text": "Tinción para CD20\n(verde) y CD35 (rojo)",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "351",
                    "parent": "349",
                    "text": "Ausencia de células\nCD35 en timo control",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "352",
                    "parent": "349",
                    "text": "Centros germinales más extensos en\npacientes AChR-Ab positivos",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "353",
                    "parent": "349",
                    "text": "Centros germinales encontrados solo en\n4/14 timos MuSK examinados",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "354",
                "parent": "345",
                "text": "Conclusión: debido a la falta de\npatología tímica, timectomía no está\nindicada en MuSK MG",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "355",
            "parent": "328",
            "text": "Panel C: Rol en cascada\nfisiopatológica de MuSK MG",
            "guid": "",
            "children": [
              {
                "id": "356",
                "parent": "355",
                "text": "I. Producción de\nanticuerpos patogénicos",
                "guid": "",
                "children": [
                  {
                    "id": "357",
                    "parent": "356",
                    "text": "Célula presentadora de\nantígeno (APC)",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "358",
                    "parent": "356",
                    "text": "Célula T",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "359",
                    "parent": "356",
                    "text": "Célula B (inhibida por\ncélulas CD20)",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "360",
                    "parent": "356",
                    "text": "Centro germinal",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "361",
                "parent": "355",
                "text": "II. Reciclaje de IgG",
                "guid": "",
                "children": [
                  {
                    "id": "362",
                    "parent": "361",
                    "text": "Receptores Fc neonatales",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "363",
                    "parent": "361",
                    "text": "Mecanismo de\ninhibición FcRN",
                    "guid": "",
                    "children": [
                      {
                        "id": "364",
                        "parent": "363",
                        "text": "Bloqueo del\nreciclaje de IgG",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "365",
                        "parent": "363",
                        "text": "Anticuerpos patogénicos no pueden unirse\na receptores FcRN ocupados",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "366",
                        "parent": "363",
                        "text": "Degradación en\nlugar de reciclaje",
                        "guid": "",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "id": "367",
                "parent": "355",
                "text": "III. Bloqueo de unión\nneuromuscular (NMJ)",
                "guid": "",
                "children": [
                  {
                    "id": "368",
                    "parent": "367",
                    "text": "Unión AChR-anticuerpo",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "369",
                    "parent": "367",
                    "text": "Mono y bivalencia pueden\naumentar patogenicidad",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "370",
                    "parent": "367",
                    "text": "Mecanismo de acción",
                    "guid": "",
                    "children": [
                      {
                        "id": "371",
                        "parent": "370",
                        "text": "Vía bloqueo de receptor",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "372",
                        "parent": "370",
                        "text": "Impedimento de\nagrupación de\nreceptores",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "373",
                        "parent": "370",
                        "text": "Alteración de fosforilación",
                        "guid": "",
                        "children": []
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "id": "374",
        "parent": "0",
        "text": "Eliminación de anticuerpos culpables: eficacia\nen AChR-anticuerpo y el primer agente\nlicenciado en MuSK-anticuerpo MG",
        "guid": "",
        "children": [
          {
            "id": "375",
            "parent": "374",
            "text": "Receptor FcRN neonatal",
            "guid": "",
            "children": [
              {
                "id": "376",
                "parent": "375",
                "text": "Crítico para reciclaje de\nanticuerpos IgG circulantes",
                "guid": "",
                "children": []
              },
              {
                "id": "377",
                "parent": "375",
                "text": "Bloqueo resulta en\ndegradación lisosomal",
                "guid": "",
                "children": []
              },
              {
                "id": "378",
                "parent": "375",
                "text": "Reducción de IgG circulantes\ncomparable a intercambio de plasma",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "379",
            "parent": "374",
            "text": "Efgartigimod\n(aprobado FDA\n2021)",
            "guid": "",
            "children": [
              {
                "id": "380",
                "parent": "379",
                "text": "Fragmento Fc IgG1",
                "guid": "",
                "children": []
              },
              {
                "id": "381",
                "parent": "379",
                "text": "Administrado como\ninfusión intravenosa",
                "guid": "",
                "children": []
              },
              {
                "id": "382",
                "parent": "379",
                "text": "Afinidad de unión a receptor\nFcRN excede IgG endógena",
                "guid": "",
                "children": []
              },
              {
                "id": "383",
                "parent": "379",
                "text": "Evita retorno a circulación",
                "guid": "",
                "children": []
              },
              {
                "id": "384",
                "parent": "379",
                "text": "Ensayo fase 3 ADAPT",
                "guid": "",
                "children": [
                  {
                    "id": "385",
                    "parent": "384",
                    "text": "Mejoría clínicamente\nsignificativa en MG-ADL",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "386",
            "parent": "374",
            "text": "Rozanolixizumab",
            "guid": "",
            "children": [
              {
                "id": "387",
                "parent": "386",
                "text": "Formulación subcutánea",
                "guid": "",
                "children": []
              },
              {
                "id": "388",
                "parent": "386",
                "text": "Dirigido a FcRN",
                "guid": "",
                "children": []
              },
              {
                "id": "389",
                "parent": "386",
                "text": "mAb IgG4 humanizado",
                "guid": "",
                "children": []
              },
              {
                "id": "390",
                "parent": "386",
                "text": "Efecto paralelo\naguas abajo",
                "guid": "",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "391",
        "parent": "0",
        "text": "# Miastenia gravis en\n2025 (continuación)",
        "guid": "TDsWM1Uw0RNggQvQOIGMMg",
        "children": []
      },
      {
        "id": "392",
        "parent": "0",
        "text": "Eliminación de\nanticuerpos\n(continuación)",
        "guid": "",
        "children": [
          {
            "id": "393",
            "parent": "392",
            "text": "Rozanolixizumab",
            "guid": "",
            "children": [
              {
                "id": "394",
                "parent": "393",
                "text": "Eliminación de IgG\nendógenas por vía lisosomal",
                "guid": "",
                "children": []
              },
              {
                "id": "395",
                "parent": "393",
                "text": "Ensayo MycarinG",
                "guid": "",
                "children": [
                  {
                    "id": "396",
                    "parent": "395",
                    "text": "Mejoras significativas\ncomparado con placebo",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "397",
                    "parent": "395",
                    "text": "Escalas de resultados\nMG establecidas",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "398",
                    "parent": "395",
                    "text": "Nueva medida centrada en paciente:\nMyasthenia Gravis Symptoms PRO",
                    "guid": "",
                    "children": [
                      {
                        "id": "399",
                        "parent": "398",
                        "text": "Reconoce\nimportancia de\nfatiga",
                        "guid": "",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "400",
                    "parent": "395",
                    "text": "Reducción de niveles IgG\ntotales (60-70%)",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "401",
                    "parent": "395",
                    "text": "Reducción de anticuerpos\nespecíficos de antígeno",
                    "guid": "",
                    "children": [
                      {
                        "id": "402",
                        "parent": "401",
                        "text": "Mejor seguimiento que\ncon depuración total",
                        "guid": "",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "id": "403",
                "parent": "393",
                "text": "Efectos\nsecundarios\nprincipales",
                "guid": "",
                "children": [
                  {
                    "id": "404",
                    "parent": "403",
                    "text": "Dolor de cabeza",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "405",
                    "parent": "403",
                    "text": "Infecciones\n(pueden ser\ngraves)",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "406",
                    "parent": "403",
                    "text": "Vacunaciones vivas o atenuadas\ncontraindicadas durante tratamiento",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "407",
            "parent": "392",
            "text": "Batoclimab",
            "guid": "",
            "children": [
              {
                "id": "408",
                "parent": "407",
                "text": "Anticuerpo IgG1\nhumanizado contra\nFcRN",
                "guid": "",
                "children": []
              },
              {
                "id": "409",
                "parent": "407",
                "text": "Administración\nsubcutánea",
                "guid": "",
                "children": []
              },
              {
                "id": "410",
                "parent": "407",
                "text": "Resultados fase\n3 recientes",
                "guid": "",
                "children": [
                  {
                    "id": "411",
                    "parent": "410",
                    "text": "132 pacientes estudiados",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "412",
                    "parent": "410",
                    "text": "Mejora significativa y\nsostenida en escala MG-ADL",
                    "guid": "",
                    "children": [
                      {
                        "id": "413",
                        "parent": "412",
                        "text": "31.3% (20/64\nasignados a\nBatoclimab)",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "414",
                        "parent": "412",
                        "text": "5.2% (3/67\nasignados a\nplacebo)",
                        "guid": "",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "415",
                    "parent": "410",
                    "text": "Efectos secundarios",
                    "guid": "",
                    "children": [
                      {
                        "id": "416",
                        "parent": "415",
                        "text": "Edema periférico",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "417",
                        "parent": "415",
                        "text": "Infecciones del tracto\nrespiratorio superior e inferior",
                        "guid": "",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "418",
                    "parent": "410",
                    "text": "Aún no aprobado por FDA",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "419",
            "parent": "392",
            "text": "Ensayos de inhibidores\nFcRN aprobados",
            "guid": "",
            "children": [
              {
                "id": "420",
                "parent": "419",
                "text": "Ambos incluyeron\npacientes MuSK-MG",
                "guid": "",
                "children": [
                  {
                    "id": "421",
                    "parent": "420",
                    "text": "ADAPT: 6 pacientes",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "422",
                    "parent": "420",
                    "text": "MycarinG: 21 pacientes",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "423",
                "parent": "419",
                "text": "Rozanolixizumab (2023)",
                "guid": "",
                "children": [
                  {
                    "id": "424",
                    "parent": "423",
                    "text": "Primer agente MuSK-MG\naprobado por FDA",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "425",
                    "parent": "423",
                    "text": "Análisis de\nsubgrupo\nMycarinG",
                    "guid": "",
                    "children": [
                      {
                        "id": "426",
                        "parent": "425",
                        "text": "Pacientes MuSK mostraron mayor\nreducción en MG-ADL",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "427",
                        "parent": "425",
                        "text": "Reducción de 4-7 puntos vs. ~3\npuntos en otros grupos",
                        "guid": "",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "id": "428",
                "parent": "419",
                "text": "Cohorte Batoclimab",
                "guid": "",
                "children": [
                  {
                    "id": "429",
                    "parent": "428",
                    "text": "Número muy pequeño de\npacientes MuSK",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "id": "430",
        "parent": "0",
        "text": "Eliminación de tipos de células\nefectoras: ¿es mejor temprano?",
        "guid": "",
        "children": [
          {
            "id": "431",
            "parent": "430",
            "text": "Rituximab",
            "guid": "",
            "children": [
              {
                "id": "432",
                "parent": "431",
                "text": "mAb contra marcador CD20 en\npoblaciones de células B",
                "guid": "",
                "children": []
              },
              {
                "id": "433",
                "parent": "431",
                "text": "Bien establecido en múltiples\nenfermedades autoinmunes",
                "guid": "",
                "children": []
              },
              {
                "id": "434",
                "parent": "431",
                "text": "Uso en MG basado en evidencia\nobservacional y casos",
                "guid": "",
                "children": []
              },
              {
                "id": "435",
                "parent": "431",
                "text": "Rol prometedor\nparticularmente en\nMuSK-MG",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "436",
            "parent": "430",
            "text": "Evidencia de ensayo\ncontrolado aleatorizado (RCA)",
            "guid": "",
            "children": [
              {
                "id": "437",
                "parent": "436",
                "text": "Disponible en 2022",
                "guid": "",
                "children": []
              },
              {
                "id": "438",
                "parent": "436",
                "text": "Ensayo\nRinomax\nanti-CD20",
                "guid": "",
                "children": [
                  {
                    "id": "439",
                    "parent": "438",
                    "text": "Reclutó pacientes de\ninicio reciente",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "440",
                    "parent": "438",
                    "text": "Casi todos AChR-positivos\n(ninguno MuSK-positivo)",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "441",
                    "parent": "438",
                    "text": "25 pacientes en brazo activo más\npropensos a lograr manifestación mínima\nque 22 individuos en grupo placebo",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "442",
                "parent": "436",
                "text": "Ensayo BEAT-MG",
                "guid": "",
                "children": [
                  {
                    "id": "443",
                    "parent": "442",
                    "text": "Número similar de participantes\n(52, todos AChR-positivos)",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "444",
                    "parent": "442",
                    "text": "≥5.5 años desde\ndiagnóstico",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "445",
                    "parent": "442",
                    "text": "Sin efecto significativo entre\nplacebo y tratamiento",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "446",
                "parent": "436",
                "text": "Posible interpretación",
                "guid": "",
                "children": [
                  {
                    "id": "447",
                    "parent": "446",
                    "text": "Paradigma Rinomax aprovechó\nmomento terapéutico",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "448",
                    "parent": "446",
                    "text": "Eliminación temprana de\ncélulas efectoras",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "449",
                    "parent": "446",
                    "text": "Prevención de\nmecanismos de\nresistencia",
                    "guid": "",
                    "children": [
                      {
                        "id": "450",
                        "parent": "449",
                        "text": "Daño mediado por complemento\nen unión neuromuscular",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "451",
                        "parent": "449",
                        "text": "Maduración de células plasmáticas\nCD20-negativas en nichos protectores",
                        "guid": "",
                        "children": []
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "id": "452",
            "parent": "430",
            "text": "Evidencia en MuSK-MG",
            "guid": "",
            "children": [
              {
                "id": "453",
                "parent": "452",
                "text": "Revisión retrospectiva\nmulticéntrica (2017)",
                "guid": "",
                "children": [
                  {
                    "id": "454",
                    "parent": "453",
                    "text": "55 pacientes (cohorte grande\npara enfermedad rara)",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "455",
                    "parent": "453",
                    "text": "Pacientes tratados con Rituximab\nsignificativamente más propensos a\ntener buen resultado",
                    "guid": "",
                    "children": [
                      {
                        "id": "456",
                        "parent": "455",
                        "text": "Evaluado por estado miastenia gravis\ne intensidad de tratamiento",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "457",
                        "parent": "455",
                        "text": "38% (19/50) alcanzaron estado de\nmanifestación mínima vs. 16% (5/31)",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "458",
                        "parent": "455",
                        "text": "Menos probabilidad de requerir terapia\ncorticosteroide (29% vs. 74%)",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "459",
                        "parent": "455",
                        "text": "Dosis media menor (4.5\nmg vs. 13 mg diarios)",
                        "guid": "",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "460",
                    "parent": "453",
                    "text": "Múltiples reportes menores\ndesde revisión 2016",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "461",
                    "parent": "453",
                    "text": "Caso significativo para\nRituximab en MuSK-MG",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "id": "462",
        "parent": "0",
        "text": "Conclusión: explosión en\nterapias para MG",
        "guid": "",
        "children": [
          {
            "id": "463",
            "parent": "462",
            "text": "Desde revisión 2016, panorama terapéutico\nsignificativamente enriquecido",
            "guid": "",
            "children": []
          },
          {
            "id": "464",
            "parent": "462",
            "text": "Varios ensayos fase\nfinal en curso",
            "guid": "",
            "children": []
          },
          {
            "id": "465",
            "parent": "462",
            "text": "Nuevos agentes en\ncategorías descritas",
            "guid": "",
            "children": []
          },
          {
            "id": "466",
            "parent": "462",
            "text": "Agentes emergentes en\ncategorías establecidas en otras\nenfermedades autoinmunes",
            "guid": "",
            "children": [
              {
                "id": "467",
                "parent": "466",
                "text": "Bloqueo de receptor IL-6",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "468",
            "parent": "462",
            "text": "Nuevos enfoques",
            "guid": "",
            "children": [
              {
                "id": "469",
                "parent": "468",
                "text": "Terapia CAR T",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "470",
            "parent": "462",
            "text": "Depleción de\ncélulas B CD19",
            "guid": "",
            "children": [
              {
                "id": "471",
                "parent": "470",
                "text": "Potencial para dirigirse a\nplasmablastos secretores de\nanticuerpos",
                "guid": "",
                "children": []
              },
              {
                "id": "472",
                "parent": "470",
                "text": "Algunas células\nplasmáticas de larga\nvida",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "473",
            "parent": "462",
            "text": "Tabla 1 resume terapias importantes\nactualmente en investigación",
            "guid": "",
            "children": []
          },
          {
            "id": "474",
            "parent": "462",
            "text": "Próxima sección explorará rol\nclínico de nuevas terapias e\nintegración en guías existentes",
            "guid": "",
            "children": []
          }
        ]
      },
      {
        "id": "475",
        "parent": "0",
        "text": "# Miastenia gravis en\n2025 (continuación)",
        "guid": "N5Hk0UPZgZ0cfsgQPa4o7w",
        "children": []
      },
      {
        "id": "476",
        "parent": "0",
        "text": "Nuevos tratamientos: integración en\npráctica real y guías actualizadas",
        "guid": "",
        "children": [
          {
            "id": "477",
            "parent": "476",
            "text": "Revisión 2016",
            "guid": "",
            "children": [
              {
                "id": "478",
                "parent": "477",
                "text": "Resumía guías de buenas prácticas\neuropeas y del Reino Unido",
                "guid": "",
                "children": []
              },
              {
                "id": "479",
                "parent": "477",
                "text": "Consejos para\nmujeres embarazadas",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "480",
            "parent": "476",
            "text": "Expansión considerable de\nterapias disponibles",
            "guid": "",
            "children": [
              {
                "id": "481",
                "parent": "480",
                "text": "Necesidad de considerar\nintegración en práctica clínica",
                "guid": "",
                "children": []
              },
              {
                "id": "482",
                "parent": "480",
                "text": "Guías de práctica\nnacional/internacional",
                "guid": "",
                "children": []
              },
              {
                "id": "483",
                "parent": "480",
                "text": "Evolución esperada\ncon el tiempo",
                "guid": "",
                "children": []
              },
              {
                "id": "484",
                "parent": "480",
                "text": "Consideraciones\nrepetidas sobre:",
                "guid": "",
                "children": [
                  {
                    "id": "485",
                    "parent": "484",
                    "text": "Seguridad",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "486",
                    "parent": "484",
                    "text": "Costo",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "487",
                    "parent": "484",
                    "text": "Escalamiento",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "488",
                    "parent": "484",
                    "text": "Opciones de combinación",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "489",
            "parent": "476",
            "text": "Guía de Consenso\nInternacional actualizada\n(2020)",
            "guid": "",
            "children": [
              {
                "id": "490",
                "parent": "489",
                "text": "Incorporación de\nvisiones expertas sobre:",
                "guid": "",
                "children": [
                  {
                    "id": "491",
                    "parent": "490",
                    "text": "Timectomía",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "492",
                    "parent": "490",
                    "text": "Rituximab",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "493",
                    "parent": "490",
                    "text": "Eculizumab",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "494",
                "parent": "489",
                "text": "Resumen de\nrecomendaciones",
                "guid": "",
                "children": [
                  {
                    "id": "495",
                    "parent": "494",
                    "text": "Consideración\ntemprana de\ntimectomía",
                    "guid": "",
                    "children": [
                      {
                        "id": "496",
                        "parent": "495",
                        "text": "Pacientes 18-50 años con MG\nAChR-positivo no timomatosa",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "497",
                        "parent": "495",
                        "text": "Refleja inclusión de individuos hasta\n65 años en estudio MGTX",
                        "guid": "",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "498",
                    "parent": "494",
                    "text": "Todos pacientes con\nMG AChR-positivo",
                    "guid": "",
                    "children": [
                      {
                        "id": "499",
                        "parent": "498",
                        "text": "No respondedores o intolerantes\na inmunoterapia inicial",
                        "guid": "",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "500",
                    "parent": "494",
                    "text": "Uso temprano de Rituximab en\npacientes MuSK-positivos",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "501",
                    "parent": "494",
                    "text": "Eculizumab para MG AChR-positivo\ngeneralizada refractaria grave",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "502",
            "parent": "476",
            "text": "Guías japonesas (2022)",
            "guid": "",
            "children": [
              {
                "id": "503",
                "parent": "502",
                "text": "Incluyen Eculizumab",
                "guid": "",
                "children": [
                  {
                    "id": "504",
                    "parent": "503",
                    "text": "Consideración cuando modalidades\nestablecidas inadecuadas",
                    "guid": "",
                    "children": [
                      {
                        "id": "505",
                        "parent": "504",
                        "text": "IVIG",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "506",
                        "parent": "504",
                        "text": "Intercambio de plasma",
                        "guid": "",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "507",
                    "parent": "503",
                    "text": "Control de síntomas",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "508",
                "parent": "502",
                "text": "Destacan rol de timectomía en\nenfermedad AChR-positiva",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "509",
            "parent": "476",
            "text": "Situación de uso de\nnuevos agentes",
            "guid": "",
            "children": [
              {
                "id": "510",
                "parent": "509",
                "text": "Enfermedad refractaria",
                "guid": "",
                "children": []
              },
              {
                "id": "511",
                "parent": "509",
                "text": "Recomendaciones\nNHS Inglaterra",
                "guid": "",
                "children": [
                  {
                    "id": "512",
                    "parent": "511",
                    "text": "Enfocadas en uso de Rituximab\nen enfermedad resistente",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "513",
                "parent": "509",
                "text": "Reconocimiento creciente",
                "guid": "",
                "children": [
                  {
                    "id": "514",
                    "parent": "513",
                    "text": "Tratamiento asertivo temprano\nmejor posicionado para:",
                    "guid": "",
                    "children": [
                      {
                        "id": "515",
                        "parent": "514",
                        "text": "Control de síntomas",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "516",
                        "parent": "514",
                        "text": "Alcanzar meta de manifestación\nmínima de enfermedad",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "517",
                        "parent": "514",
                        "text": "Prednisona <5 mg/día",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "518",
                        "parent": "514",
                        "text": "Limitar daño permanente en\nunión neuromuscular",
                        "guid": "",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "519",
                    "parent": "513",
                    "text": "Beneficios tangibles en\nenfermedad grave",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "520",
                    "parent": "513",
                    "text": "Estabilización rápida",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "id": "521",
        "parent": "0",
        "text": "Algoritmo de tratamiento\npara MG (Fig. 4)",
        "guid": "",
        "children": [
          {
            "id": "522",
            "parent": "521",
            "text": "Diagnóstico clínico, laboratorio y\nradiológico de MG generalizada",
            "guid": "",
            "children": [
              {
                "id": "523",
                "parent": "522",
                "text": "Consideraciones para\nAChR-Ab y MuSK",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "524",
            "parent": "521",
            "text": "Inducción y mantenimiento\n(primeros 6-12 meses)",
            "guid": "",
            "children": [
              {
                "id": "525",
                "parent": "524",
                "text": "Inicio de terapia\nsintomática",
                "guid": "",
                "children": [
                  {
                    "id": "526",
                    "parent": "525",
                    "text": "Si hay respuesta\ny es tolerada",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "527",
                "parent": "524",
                "text": "Timectomía si:",
                "guid": "",
                "children": [
                  {
                    "id": "528",
                    "parent": "527",
                    "text": "<50 años (o <65)",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "529",
                    "parent": "527",
                    "text": "Timoma (cualquier edad)",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "530",
                    "parent": "527",
                    "text": "Realizar ASAP\n(2-6 meses)",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "531",
                    "parent": "527",
                    "text": "Nota: sin rol para\ntimectomía en MuSK-MG",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "532",
                "parent": "524",
                "text": "Sin respuesta pronta o\nrespuesta en espera:",
                "guid": "",
                "children": [
                  {
                    "id": "533",
                    "parent": "532",
                    "text": "+/- inmunosupresión\noral / anti-CD20",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "534",
                    "parent": "532",
                    "text": "Consideración de dosis reducida\nanti-CD20 en pacientes ancianos",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "535",
                "parent": "524",
                "text": "Sin respuesta significativa o\nremisión en 10-12 meses:",
                "guid": "",
                "children": [
                  {
                    "id": "536",
                    "parent": "535",
                    "text": "Otro agente\ninmunosupresor oral /\nanti-CD20",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "537",
                "parent": "524",
                "text": "Sin respuesta significativa o\nremisión en 10-12 meses:",
                "guid": "",
                "children": [
                  {
                    "id": "538",
                    "parent": "537",
                    "text": "O efectos secundarios graves a 3\ntipos diferentes de terapias:",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "539",
                    "parent": "537",
                    "text": "Nuevas terapias \"dirigidas\"",
                    "guid": "",
                    "children": [
                      {
                        "id": "540",
                        "parent": "539",
                        "text": "Inhibidor del complemento\n(solo pacientes AChR-Ab)",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "541",
                        "parent": "539",
                        "text": "Inhibidor FcRn",
                        "guid": "",
                        "children": []
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "id": "542",
            "parent": "521",
            "text": "Crisis MG durante terapia crónica\nestablecida sin desencadenante claro",
            "guid": "",
            "children": [
              {
                "id": "543",
                "parent": "542",
                "text": "Consideración de nuevas\nterapias dirigidas",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "544",
            "parent": "521",
            "text": "Notas importantes",
            "guid": "",
            "children": [
              {
                "id": "545",
                "parent": "544",
                "text": "IVIG y PLEX usarse:",
                "guid": "",
                "children": [
                  {
                    "id": "546",
                    "parent": "545",
                    "text": "En diagnóstico si MG grave (mientras se\nespera que línea sea efectiva)",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "547",
                    "parent": "545",
                    "text": "En crisis MG",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "548",
                    "parent": "545",
                    "text": "Pre-cirugía (algunos)",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "549",
                "parent": "544",
                "text": "IVIG y PLEX no son\nterapias crónicas",
                "guid": "",
                "children": [
                  {
                    "id": "550",
                    "parent": "549",
                    "text": "Uso desaconsejado por falta de\nmejores tratamientos",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "551",
                "parent": "544",
                "text": "Espacio NHSE para IVIG:",
                "guid": "",
                "children": [
                  {
                    "id": "552",
                    "parent": "551",
                    "text": "Solo para crisis MG\ny pre-cirugía",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "553",
            "parent": "521",
            "text": "Guías alemanas\nactualizadas",
            "guid": "",
            "children": [
              {
                "id": "554",
                "parent": "553",
                "text": "Enfoque comparable",
                "guid": "",
                "children": []
              },
              {
                "id": "555",
                "parent": "553",
                "text": "Detalle de\nabreviaturas\nutilizadas:",
                "guid": "",
                "children": [
                  {
                    "id": "556",
                    "parent": "555",
                    "text": "Ab: anticuerpo",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "557",
                    "parent": "555",
                    "text": "AChR: receptor\nde acetilcolina",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "558",
                    "parent": "555",
                    "text": "FcRN: receptor\nFc neonatal",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "559",
                    "parent": "555",
                    "text": "gMG: Miastenia\nGravis generalizada",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "560",
                    "parent": "555",
                    "text": "IVIG:\ninmunoglobulina\nintravenosa",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "561",
                    "parent": "555",
                    "text": "MuSK: quinasa\nespecífica muscular",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "562",
                    "parent": "555",
                    "text": "NHSE: Servicio Nacional\nde Salud Inglaterra",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "563",
                    "parent": "555",
                    "text": "PLEX:\nintercambio de\nplasma",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "564",
                    "parent": "555",
                    "text": "thx: timectomía",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "id": "565",
        "parent": "0",
        "text": "# Miastenia gravis en\n2025 (continuación)",
        "guid": "Mp7dO1_GBawdvQw-f0iE0w",
        "children": []
      },
      {
        "id": "566",
        "parent": "0",
        "text": "Consideraciones sobre uso\nde nuevas terapias",
        "guid": "",
        "children": [
          {
            "id": "567",
            "parent": "566",
            "text": "Ensayos de Rituximab",
            "guid": "",
            "children": [
              {
                "id": "568",
                "parent": "567",
                "text": "Ventaja potencial de\ntratamiento temprano",
                "guid": "",
                "children": []
              },
              {
                "id": "569",
                "parent": "567",
                "text": "Prevención de debilidad\nmuscular permanente",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "570",
            "parent": "566",
            "text": "Requerimientos de terapia\nmáxima personalizados",
            "guid": "",
            "children": [
              {
                "id": "571",
                "parent": "570",
                "text": "Factores a considerar",
                "guid": "",
                "children": [
                  {
                    "id": "572",
                    "parent": "571",
                    "text": "Edad",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "573",
                    "parent": "571",
                    "text": "Ocupación",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "574",
                    "parent": "571",
                    "text": "Rendimiento funcional",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "575",
                    "parent": "571",
                    "text": "Objetivos de vida",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "576",
                    "parent": "571",
                    "text": "Creencias sobre\nenfermedad",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "577",
                    "parent": "571",
                    "text": "Severidad de enfermedad",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "578",
            "parent": "566",
            "text": "Representación variable de\npacientes mayores en ensayos",
            "guid": "",
            "children": [
              {
                "id": "579",
                "parent": "578",
                "text": "MGTX y Zilucoplan: límite\nsuperior 65 y 74 años",
                "guid": "",
                "children": []
              },
              {
                "id": "580",
                "parent": "578",
                "text": "Otros sin límite\nsuperior de edad",
                "guid": "",
                "children": []
              },
              {
                "id": "581",
                "parent": "578",
                "text": "Edades promedio reflejan demografía\nmás joven (20-30 o 50 años)",
                "guid": "",
                "children": []
              },
              {
                "id": "582",
                "parent": "578",
                "text": "Ensayo Rinomax: más\ninclusivo con ancianos",
                "guid": "",
                "children": [
                  {
                    "id": "583",
                    "parent": "582",
                    "text": "Media de 67.4 años en\nbrazo tratamiento",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "584",
                    "parent": "582",
                    "text": "Desviación\nestándar 13.4\naños",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "585",
                    "parent": "582",
                    "text": "Mejor representación de\ndemografía actual de MG",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "586",
            "parent": "566",
            "text": "Efecto clínico de inhibición\ndel complemento",
            "guid": "",
            "children": [
              {
                "id": "587",
                "parent": "586",
                "text": "Aparente dentro de\nuna semana",
                "guid": "",
                "children": []
              },
              {
                "id": "588",
                "parent": "586",
                "text": "Todos agentes aprobados",
                "guid": "",
                "children": [
                  {
                    "id": "589",
                    "parent": "588",
                    "text": "Eculizumab",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "590",
                    "parent": "588",
                    "text": "Ravulizumab",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "591",
                    "parent": "588",
                    "text": "Zilucoplan",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "592",
                "parent": "586",
                "text": "Inhibición FcRN",
                "guid": "",
                "children": [
                  {
                    "id": "593",
                    "parent": "592",
                    "text": "Reducción de IgG\ncirculantes totales",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "594",
                    "parent": "592",
                    "text": "Reducción anticuerpos\nespecíficos de antígeno",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "595",
                    "parent": "592",
                    "text": "Similar en tiempo y proporción a\nintercambio de plasma",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "596",
                    "parent": "592",
                    "text": "Eliminación de riesgos asociados\ncon intercambio de plasma",
                    "guid": "",
                    "children": [
                      {
                        "id": "597",
                        "parent": "596",
                        "text": "Cambios de volumen",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "598",
                        "parent": "596",
                        "text": "Infecciones de línea",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "599",
                        "parent": "596",
                        "text": "Sangrado",
                        "guid": "",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "600",
                    "parent": "592",
                    "text": "Particularmente útil en\npoblación anciana",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "601",
                "parent": "586",
                "text": "Aspecto importante de inhibición\nFcRN y complemento",
                "guid": "",
                "children": [
                  {
                    "id": "602",
                    "parent": "601",
                    "text": "Probablemente\nmodalidades a largo\nplazo",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "603",
                    "parent": "601",
                    "text": "No abordan\ncausa celular raíz",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "604",
                    "parent": "601",
                    "text": "Rol en escenario hiperagudo\npermanece inexplorado",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "605",
                "parent": "586",
                "text": "Criterios de\nentrada en\nensayos",
                "guid": "",
                "children": [
                  {
                    "id": "606",
                    "parent": "605",
                    "text": "Clase MGFA II-IV (debilidad leve\na grave generalizada)",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "607",
                    "parent": "605",
                    "text": "Enfermedad estable por al\nmenos 4 semanas",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "608",
                    "parent": "605",
                    "text": "Algunos ensayos explícitamente\nexcluyen pacientes en crisis",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "609",
                    "parent": "605",
                    "text": "Rozanolixizumab\nespecifica máximo clase\nIVa",
                    "guid": "",
                    "children": [
                      {
                        "id": "610",
                        "parent": "609",
                        "text": "Excluye pacientes con síntomas\nbulbar/respiratorios predominantes",
                        "guid": "",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "611",
                    "parent": "605",
                    "text": "Protocolos permitieron uso concurrente\nde terapias estándar y rescate",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "612",
            "parent": "566",
            "text": "Nuevas guías\neuropeas principales",
            "guid": "",
            "children": [
              {
                "id": "613",
                "parent": "612",
                "text": "Guías alemanas (2023)",
                "guid": "",
                "children": [
                  {
                    "id": "614",
                    "parent": "613",
                    "text": "Evaluación de actividad de enfermedad\nmediante herramientas validadas",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "615",
                    "parent": "613",
                    "text": "Uso de nuevos agentes en pacientes\nmuy activos o refractarios",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "616",
                "parent": "612",
                "text": "Guías nórdicas (2024)",
                "guid": "",
                "children": [
                  {
                    "id": "617",
                    "parent": "616",
                    "text": "Rituximab en dosis únicas <500 mg\nal inicio de enfermedad",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "618",
                    "parent": "616",
                    "text": "Alternativa a\nesteroides y\nazatioprina",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "619",
                    "parent": "616",
                    "text": "Disponibilidad de inhibidores de\ncomplemento y FcRN\ndependiente de factores locales",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "620",
                    "parent": "616",
                    "text": "Reservados para\npacientes difíciles de\ntratar",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "621",
                    "parent": "616",
                    "text": "Énfasis en rol de\ntimectomía",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "622",
                "parent": "612",
                "text": "Guías ABN del\nReino Unido (2015)",
                "guid": "",
                "children": [
                  {
                    "id": "623",
                    "parent": "622",
                    "text": "Requieren actualización",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "624",
                "parent": "612",
                "text": "Guías actualizadas",
                "guid": "",
                "children": [
                  {
                    "id": "625",
                    "parent": "624",
                    "text": "Valiosas como marco para\ndecisiones individualizadas",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "626",
                    "parent": "624",
                    "text": "Factores a nivel\nde paciente",
                    "guid": "",
                    "children": [
                      {
                        "id": "627",
                        "parent": "626",
                        "text": "Duración de enfermedad",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "628",
                        "parent": "626",
                        "text": "Severidad",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "629",
                        "parent": "626",
                        "text": "Medicaciones\ninmunosupresoras pasadas y\nactuales",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "630",
                        "parent": "626",
                        "text": "Comorbilidades",
                        "guid": "",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "631",
                    "parent": "624",
                    "text": "Prevalencia creciente de MG\nde inicio tardío (LOMG)",
                    "guid": "",
                    "children": [
                      {
                        "id": "632",
                        "parent": "631",
                        "text": "Requiere consideración\ncuidadosa para terapia esteroide",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "633",
                        "parent": "631",
                        "text": "Inmunoterapia en\npacientes ancianos",
                        "guid": "",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "634",
                    "parent": "624",
                    "text": "Aumento de\nnuevas terapias",
                    "guid": "",
                    "children": [
                      {
                        "id": "635",
                        "parent": "634",
                        "text": "Relaciones de trabajo estrechas entre\nneurólogos generales y especialistas",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "636",
                        "parent": "634",
                        "text": "Centros terciarios asesoran en\ntodas las etapas MG",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "637",
                        "parent": "634",
                        "text": "Balance entre derivación\napropiada y apoyo local",
                        "guid": "",
                        "children": []
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "id": "638",
        "parent": "0",
        "text": "Biomarcadores: hacia\ntratamiento de precisión en MG",
        "guid": "",
        "children": [
          {
            "id": "639",
            "parent": "638",
            "text": "Biomarcadores\nexploratorios en\ninvestigación",
            "guid": "",
            "children": [
              {
                "id": "640",
                "parent": "639",
                "text": "Distantes de uso clínico",
                "guid": "",
                "children": []
              },
              {
                "id": "641",
                "parent": "639",
                "text": "A pesar de actividad\ninvestigativa significativa",
                "guid": "",
                "children": []
              },
              {
                "id": "642",
                "parent": "639",
                "text": "Perfiles emergentes",
                "guid": "",
                "children": []
              },
              {
                "id": "643",
                "parent": "639",
                "text": "ARNm circulantes",
                "guid": "",
                "children": [
                  {
                    "id": "644",
                    "parent": "643",
                    "text": "Requieren estandarización de\nlaboratorio multicentro",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "645",
                    "parent": "643",
                    "text": "Estudios para\nganar credibilidad",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "646",
            "parent": "638",
            "text": "Biomarcadores más estudiados y\npróximos al uso clínico",
            "guid": "",
            "children": [
              {
                "id": "647",
                "parent": "646",
                "text": "Repertorio de células\ninmunes circulantes",
                "guid": "",
                "children": []
              },
              {
                "id": "648",
                "parent": "646",
                "text": "Respuesta humoral",
                "guid": "",
                "children": []
              },
              {
                "id": "649",
                "parent": "646",
                "text": "Subconjuntos de células B",
                "guid": "",
                "children": [
                  {
                    "id": "650",
                    "parent": "649",
                    "text": "Medidos rutinariamente en práctica\nclínica con uso de Rituximab",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "651",
                "parent": "646",
                "text": "Niveles de IgG",
                "guid": "",
                "children": []
              },
              {
                "id": "652",
                "parent": "646",
                "text": "Caracterización de\ncélulas inmunes",
                "guid": "",
                "children": [
                  {
                    "id": "653",
                    "parent": "652",
                    "text": "Incorporadas en ensayos recientes\ny diseños de protocolos",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "654",
                "parent": "646",
                "text": "Polimorfismos genéticos",
                "guid": "",
                "children": [
                  {
                    "id": "655",
                    "parent": "654",
                    "text": "Pueden predecir respuesta\na algunas terapias",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "656",
                    "parent": "654",
                    "text": "Polimorfismos FCGR3A como\nimpacto en relapso de Rituximab",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "657",
                    "parent": "654",
                    "text": "Requerimientos de dosificación en\npacientes coreanos con mielitis óptica",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "658",
                    "parent": "654",
                    "text": "Mutación en C5\n(c.2654G>A)",
                    "guid": "",
                    "children": [
                      {
                        "id": "659",
                        "parent": "658",
                        "text": "Configura\npolimorfismo p.\nArg885His",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "660",
                        "parent": "658",
                        "text": "Elimina unión de\nEculizumab",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "661",
                        "parent": "658",
                        "text": "Subyace respuesta deficiente en\npacientes japoneses y chinos",
                        "guid": "",
                        "children": []
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "id": "662",
        "parent": "0",
        "text": "Progreso y imagen más\nclara en MuSK-MG",
        "guid": "",
        "children": [
          {
            "id": "663",
            "parent": "662",
            "text": "Revisión anterior",
            "guid": "",
            "children": [
              {
                "id": "664",
                "parent": "663",
                "text": "Anticuerpos MuSK considerados reflejo\nde actividad de enfermedad",
                "guid": "",
                "children": []
              },
              {
                "id": "665",
                "parent": "663",
                "text": "Títulos correlacionados\npositivamente con severidad",
                "guid": "",
                "children": []
              },
              {
                "id": "666",
                "parent": "663",
                "text": "Alteración con inmunoterapia en\npacientes individuales",
                "guid": "",
                "children": []
              },
              {
                "id": "667",
                "parent": "663",
                "text": "Disminución con el tiempo",
                "guid": "",
                "children": []
              },
              {
                "id": "668",
                "parent": "663",
                "text": "Algunos pacientes\nseronegativizados",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "669",
            "parent": "662",
            "text": "Informes recientes",
            "guid": "",
            "children": [
              {
                "id": "670",
                "parent": "669",
                "text": "Delimitación de rol en\npredicción de recaída",
                "guid": "",
                "children": []
              },
              {
                "id": "671",
                "parent": "669",
                "text": "Necesidad de estudios\nmás completos",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "672",
            "parent": "662",
            "text": "Cribado detallado y mapeo epitópico\nde anticuerpos anti-MuSK",
            "guid": "",
            "children": [
              {
                "id": "673",
                "parent": "672",
                "text": "Mayor comprensión mediante\ndelineación específica",
                "guid": "",
                "children": []
              },
              {
                "id": "674",
                "parent": "672",
                "text": "Relación entre anticuerpos a dominio\nIg1 de MuSK y severidad",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "675",
            "parent": "662",
            "text": "Importancia para mecanismos\nfisiopatológicos subyacentes",
            "guid": "",
            "children": [
              {
                "id": "676",
                "parent": "675",
                "text": "Dominio esencial para\ninteracción de MuSK con LRP4",
                "guid": "",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "677",
        "parent": "0",
        "text": "# Miastenia gravis en\n2025 (continuación)",
        "guid": "frA3iywMago05CT-F3sSCQ",
        "children": []
      },
      {
        "id": "678",
        "parent": "0",
        "text": "Tabla 2: Biomarcadores\nexploratorios en MG",
        "guid": "",
        "children": []
      },
      {
        "id": "679",
        "parent": "0",
        "text": "Biomarcadores\nmicroARN (miRNAs)",
        "guid": "",
        "children": [
          {
            "id": "680",
            "parent": "679",
            "text": "Utilidad potencial\ny subtipo MG",
            "guid": "",
            "children": [
              {
                "id": "681",
                "parent": "680",
                "text": "Diagnóstico de MG ocular\nvs. MG generalizada",
                "guid": "",
                "children": []
              },
              {
                "id": "682",
                "parent": "680",
                "text": "Diagnóstico de\nMuSK + MG",
                "guid": "",
                "children": []
              },
              {
                "id": "683",
                "parent": "680",
                "text": "Respuesta al tratamiento\nen AChR Ab + MG",
                "guid": "",
                "children": []
              },
              {
                "id": "684",
                "parent": "680",
                "text": "Progresión de enfermedad y\nrespuesta al tratamiento en LOMG",
                "guid": "",
                "children": []
              },
              {
                "id": "685",
                "parent": "680",
                "text": "Diferenciación entre MG ocular y MG\ngeneralizada secundaria",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "686",
            "parent": "679",
            "text": "Resumen de hallazgos",
            "guid": "",
            "children": [
              {
                "id": "687",
                "parent": "686",
                "text": "Fase 3 de ensayo en\ncurso (NCT05888558)",
                "guid": "",
                "children": []
              },
              {
                "id": "688",
                "parent": "686",
                "text": "Aumento de suero let-7 miR-let-7a-5p, miR-let-7f-5p,\nmiR-423-5p y miR-151a-5p en cohorte MuSK-MG\ncomparado con controles sanos",
                "guid": "",
                "children": []
              },
              {
                "id": "689",
                "parent": "686",
                "text": "Aumento de suero miR-150-5p y\nmiR-21-5p en MG comparado\ncon controles sanos",
                "guid": "",
                "children": []
              },
              {
                "id": "690",
                "parent": "686",
                "text": "Disminución de\nmiR-150-5p\npost-timectomía",
                "guid": "",
                "children": []
              },
              {
                "id": "691",
                "parent": "686",
                "text": "Disminución de miR-150-5p exosomal\nen paralelo con mejoría clínica tras\ntratamiento con Rituximab",
                "guid": "",
                "children": []
              },
              {
                "id": "692",
                "parent": "686",
                "text": "Disminución de miR-150-5p y\nmiR-21-5p en grupo MG\ninmunosuprimido vs. no\ninmunosuprimido",
                "guid": "",
                "children": []
              },
              {
                "id": "693",
                "parent": "686",
                "text": "Disminución significativa de miR-323b-3p,\n-409-3p y -485-3p en inmunosupresión\nno-responsiva vs. grupo responsivo",
                "guid": "",
                "children": []
              },
              {
                "id": "694",
                "parent": "686",
                "text": "Aumento significativo de\nmiR-181d-5p y -340-3p en grupo\nno-responsivo a inmunosupresión",
                "guid": "",
                "children": []
              },
              {
                "id": "695",
                "parent": "686",
                "text": "Correlación negativa de miR-150-5p,\nmiR-21-5p y miR-30e-5p con puntuación\nMGC tras inmunosupresión",
                "guid": "",
                "children": []
              },
              {
                "id": "696",
                "parent": "686",
                "text": "Alta sensibilidad de miR-30e-5p en\ndiferenciación de MG ocular y MG\ngeneralizada secundaria",
                "guid": "",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "697",
        "parent": "0",
        "text": "Proteínas de choque térmico\n(Heat shock proteins)",
        "guid": "",
        "children": [
          {
            "id": "698",
            "parent": "697",
            "text": "Utilidad potencial\ny subtipo MG",
            "guid": "",
            "children": [
              {
                "id": "699",
                "parent": "698",
                "text": "HSC 71: Progresión de\nenfermedad y respuesta al\ntratamiento en MG generalizada",
                "guid": "",
                "children": []
              },
              {
                "id": "700",
                "parent": "698",
                "text": "HSP90α: Respuesta al tratamiento en MG\ntimomatosa y no-timomatosa",
                "guid": "",
                "children": []
              },
              {
                "id": "701",
                "parent": "698",
                "text": "HSP 70:\nDiagnóstico de\nMG",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "702",
            "parent": "697",
            "text": "Resumen de hallazgos",
            "guid": "",
            "children": [
              {
                "id": "703",
                "parent": "702",
                "text": "Aumento significativo de anticuerpos\nanti-proteína 71 de choque térmico (HSC71) en\nMG generalizada vs. controles sanos",
                "guid": "",
                "children": []
              },
              {
                "id": "704",
                "parent": "702",
                "text": "Disminución significativa de anticuerpos\nHSC71 en paralelo con mejoría clínica",
                "guid": "",
                "children": []
              },
              {
                "id": "705",
                "parent": "702",
                "text": "Asociación de terapia con tacrolimus en pacientes\nrefractarios a inhibidores de acetilcolinesterasa con\nmejoría clínica y reducción de títulos HSC71",
                "guid": "",
                "children": []
              },
              {
                "id": "706",
                "parent": "702",
                "text": "Aumento significativo de suero HSP90α en\npacientes con MG timomatosa y\nno-timomatosa vs. controles sanos",
                "guid": "",
                "children": []
              },
              {
                "id": "707",
                "parent": "702",
                "text": "Asociación de títulos altos de HSP90α\ncon aumento de recurrencia tumoral en\npacientes con timoma",
                "guid": "",
                "children": []
              },
              {
                "id": "708",
                "parent": "702",
                "text": "Correlación de resección tumoral completa con\ndisminución de títulos HSP90α",
                "guid": "",
                "children": []
              },
              {
                "id": "709",
                "parent": "702",
                "text": "Aumento significativo de concentraciones séricas\nHSP90α preoperatorias en pacientes no\nrespondedores a timectomía vs. respondedores",
                "guid": "",
                "children": []
              },
              {
                "id": "710",
                "parent": "702",
                "text": "Aumento de títulos de anticuerpos anti-HSP70 en MG\ny síndrome de Guillain-Barré vs. controles sanos y\npacientes con esclerosis múltiple",
                "guid": "",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "711",
        "parent": "0",
        "text": "Cadena ligera de\nneurofilamento",
        "guid": "",
        "children": [
          {
            "id": "712",
            "parent": "711",
            "text": "Utilidad potencial\ny subtipo MG",
            "guid": "",
            "children": [
              {
                "id": "713",
                "parent": "712",
                "text": "Progresión de enfermedad en\nadultos 18+ con MG",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "714",
            "parent": "711",
            "text": "Resumen de hallazgos",
            "guid": "",
            "children": [
              {
                "id": "715",
                "parent": "714",
                "text": "Elevación de títulos de cadena ligera\nde neurofilamento séricos en cohorte\nMG vs. controles sanos",
                "guid": "",
                "children": []
              },
              {
                "id": "716",
                "parent": "714",
                "text": "Sin asociación estadística entre\ntítulos y estado clínico\n(puntuaciones QMG y MG-ADL)",
                "guid": "",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "717",
        "parent": "0",
        "text": "Marcadores intestinales",
        "guid": "",
        "children": [
          {
            "id": "718",
            "parent": "717",
            "text": "Utilidad potencial\ny subtipo MG",
            "guid": "",
            "children": [
              {
                "id": "719",
                "parent": "718",
                "text": "Susceptibilidad a enfermedad,\ncomparación con controles sanos y\nposibles objetivos terapéuticos",
                "guid": "",
                "children": []
              },
              {
                "id": "720",
                "parent": "718",
                "text": "Diagnóstico y progresión de enfermedad\nen todos los subtipos de MG",
                "guid": "",
                "children": []
              },
              {
                "id": "721",
                "parent": "718",
                "text": "Diagnóstico de MG ocular\ny MG generalizada",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "722",
            "parent": "717",
            "text": "Resumen de hallazgos",
            "guid": "",
            "children": [
              {
                "id": "723",
                "parent": "722",
                "text": "Varios estudios muestran microbiota\nfecal alterada, diversidad reducida y\ndisbiosis en MG vs. controles",
                "guid": "",
                "children": []
              },
              {
                "id": "724",
                "parent": "722",
                "text": "Relaciones específicas incluyen\nposibles roles etiológicos para\nLachnoclostridium y Faecalibacterium",
                "guid": "",
                "children": []
              },
              {
                "id": "725",
                "parent": "722",
                "text": "Objetivos de intervención potenciales:\nBacteroidetes y Desulfovibrionaceae",
                "guid": "",
                "children": []
              },
              {
                "id": "726",
                "parent": "722",
                "text": "Títulos elevados de marcadores\ninflamatorios sistémicos en MG,\ncorrelacionados con disbiosis intestinal",
                "guid": "",
                "children": []
              },
              {
                "id": "727",
                "parent": "722",
                "text": "Aumento de portación de ciertas\nespecies incluyendo Streptococcus",
                "guid": "",
                "children": []
              },
              {
                "id": "728",
                "parent": "722",
                "text": "Panel de biomarcadores microbianos y metabólicos de\nmuestras fecales capaz de discriminar MG y controles\nsanos con 100% de precisión",
                "guid": "",
                "children": []
              },
              {
                "id": "729",
                "parent": "722",
                "text": "Correlación negativa de varios índices\nde diversidad microbiana con\npuntuaciones QMG aumentadas",
                "guid": "",
                "children": []
              },
              {
                "id": "730",
                "parent": "722",
                "text": "Panel de biomarcadores microbianos y\nmetabólicos capaz de discriminar MG\nocular y MG generalizada",
                "guid": "",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "731",
        "parent": "0",
        "text": "EMG de fibra única",
        "guid": "",
        "children": [
          {
            "id": "732",
            "parent": "731",
            "text": "Utilidad potencial\ny subtipo MG",
            "guid": "",
            "children": [
              {
                "id": "733",
                "parent": "732",
                "text": "Respuesta al tratamiento en\nMG seronegativa ocular",
                "guid": "",
                "children": []
              },
              {
                "id": "734",
                "parent": "732",
                "text": "Progresión de enfermedad\nen MG AChR+ leve",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "735",
            "parent": "731",
            "text": "Resumen de hallazgos",
            "guid": "",
            "children": [
              {
                "id": "736",
                "parent": "735",
                "text": "Aumento de jitter SFEMG de orbicularis\noculi en pacientes con alto valor predictivo\npara respuesta terapéutica",
                "guid": "",
                "children": []
              },
              {
                "id": "737",
                "parent": "735",
                "text": "Asociación de jitter aumentado y\nbloqueo aumentado con\nexacerbaciones de enfermedad",
                "guid": "",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "738",
        "parent": "0",
        "text": "Datos de smartphone",
        "guid": "",
        "children": [
          {
            "id": "739",
            "parent": "738",
            "text": "Utilidad potencial\ny subtipo MG",
            "guid": "",
            "children": [
              {
                "id": "740",
                "parent": "739",
                "text": "Estado de enfermedad y\nexacerbación en adultos 18+ con MG",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "741",
            "parent": "738",
            "text": "Resumen de hallazgos",
            "guid": "",
            "children": [
              {
                "id": "742",
                "parent": "741",
                "text": "Estudio piloto para fenotipificar pacientes MG y recopilar\nmarcadores digitales de exacerbación inminente vía\nrecolección de datos por smartphone",
                "guid": "",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "743",
        "parent": "0",
        "text": "{Continuación del esquema\nde miastenia gravis}",
        "guid": "dJnIzAwtC5pMrC__C3XFbA",
        "children": []
      },
      {
        "id": "744",
        "parent": "0",
        "text": "Patogénesis de anticuerpos\nMuSK (continuación)",
        "guid": "",
        "children": [
          {
            "id": "745",
            "parent": "744",
            "text": "Anticuerpos patogénicos a\ndominio IgG-like 2",
            "guid": "",
            "children": [
              {
                "id": "746",
                "parent": "745",
                "text": "Implicados en\ncohortes pequeñas",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "747",
            "parent": "744",
            "text": "Subpoblación de\nanticuerpos MuSK",
            "guid": "",
            "children": [
              {
                "id": "748",
                "parent": "747",
                "text": "Activan fosforilación MuSK",
                "guid": "",
                "children": []
              },
              {
                "id": "749",
                "parent": "747",
                "text": "Inducen cierto grado de\nagrupación AChR",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "750",
            "parent": "744",
            "text": "Anticuerpos bivalentes\nno patogénicos",
            "guid": "",
            "children": [
              {
                "id": "751",
                "parent": "750",
                "text": "Adquieren potencial patogénico\ndespués de cambio en brazo FAB",
                "guid": "",
                "children": []
              },
              {
                "id": "752",
                "parent": "750",
                "text": "Propiedad única de\nsubclase IgG4",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "753",
            "parent": "744",
            "text": "Mayoría de\nanticuerpos\nMuSK-MG",
            "guid": "",
            "children": [
              {
                "id": "754",
                "parent": "753",
                "text": "Subclase IgG4",
                "guid": "",
                "children": []
              },
              {
                "id": "755",
                "parent": "753",
                "text": "Papel de subclase IgG3 en\nreconocimiento LRP4",
                "guid": "",
                "children": []
              },
              {
                "id": "756",
                "parent": "753",
                "text": "Comparable a\nentidades IgG4",
                "guid": "",
                "children": []
              },
              {
                "id": "757",
                "parent": "753",
                "text": "Inhibición de\nagrupación AChR",
                "guid": "",
                "children": []
              },
              {
                "id": "758",
                "parent": "753",
                "text": "Mayor potencia potencial",
                "guid": "",
                "children": []
              },
              {
                "id": "759",
                "parent": "753",
                "text": "Vía no canónica diferente",
                "guid": "",
                "children": []
              },
              {
                "id": "760",
                "parent": "753",
                "text": "Posible complementación",
                "guid": "",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "761",
        "parent": "0",
        "text": "Trabajo intensivo sobre fenotipos\nespecíficos de células B",
        "guid": "",
        "children": [
          {
            "id": "762",
            "parent": "761",
            "text": "Clones que pueden ser\nfundamentales en heraldo y\nrecaída",
            "guid": "",
            "children": []
          },
          {
            "id": "763",
            "parent": "761",
            "text": "Apoyado por varias\nlíneas de evidencia",
            "guid": "",
            "children": []
          },
          {
            "id": "764",
            "parent": "761",
            "text": "Clones IgG4 B\nespecíficos de\nantígeno",
            "guid": "",
            "children": [
              {
                "id": "765",
                "parent": "764",
                "text": "Dirigidos al dominio\nIgG-like 1 de MuSK",
                "guid": "",
                "children": []
              },
              {
                "id": "766",
                "parent": "764",
                "text": "Emergentes antes del\ndebilitamiento clínico",
                "guid": "",
                "children": []
              },
              {
                "id": "767",
                "parent": "764",
                "text": "Pacientes MuSK-MG tratados con\ntrasplante de médula ósea",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "768",
            "parent": "761",
            "text": "Plasmablastos CD38+ y CD27+\nresistentes a Rituximab",
            "guid": "",
            "children": []
          },
          {
            "id": "769",
            "parent": "761",
            "text": "Clones de células B CD20 bajo\nsobreviven a inmunoterapia",
            "guid": "",
            "children": []
          },
          {
            "id": "770",
            "parent": "761",
            "text": "Reconstituyen cerca y median\nrecaídas de MuSK-MG",
            "guid": "",
            "children": []
          },
          {
            "id": "771",
            "parent": "761",
            "text": "Células resistentes podrían\nactuar como biomarcadores",
            "guid": "",
            "children": []
          },
          {
            "id": "772",
            "parent": "761",
            "text": "Objetivos terapéuticos para\ncélulas CAR T de precisión",
            "guid": "",
            "children": []
          },
          {
            "id": "773",
            "parent": "761",
            "text": "Desde 2019, fenotipo más amplio de\ncélulas B posible objetivo",
            "guid": "",
            "children": []
          },
          {
            "id": "774",
            "parent": "761",
            "text": "Terapia anti-CD19, usada en trastornos del\nespectro de neuromielitis óptica",
            "guid": "",
            "children": []
          },
          {
            "id": "775",
            "parent": "761",
            "text": "Oportunidad para eliminar\ncélulas resistentes",
            "guid": "",
            "children": []
          }
        ]
      },
      {
        "id": "776",
        "parent": "0",
        "text": "Fuerza y diversidad en números:\nimagen compleja en AChR-MG",
        "guid": "",
        "children": [
          {
            "id": "777",
            "parent": "776",
            "text": "Diferencia con\nanticuerpos AChR",
            "guid": "",
            "children": []
          },
          {
            "id": "778",
            "parent": "776",
            "text": "Evidencia a\nnivel de cohorte",
            "guid": "",
            "children": [
              {
                "id": "779",
                "parent": "778",
                "text": "Títulos cuantitativos de\nanticuerpos menos relacionados\ncon actividad de enfermedad",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "780",
            "parent": "776",
            "text": "Cambios intra-individuales pueden\nser de beneficio personal en\nmonitoreo de enfermedad",
            "guid": "",
            "children": []
          },
          {
            "id": "781",
            "parent": "776",
            "text": "Tecnología actual delineando\ncon más detalle granular",
            "guid": "",
            "children": [
              {
                "id": "782",
                "parent": "781",
                "text": "Heterogeneidad mecanicista\npreviamente establecida",
                "guid": "",
                "children": []
              },
              {
                "id": "783",
                "parent": "781",
                "text": "Entre y dentro\nde individuos",
                "guid": "",
                "children": []
              },
              {
                "id": "784",
                "parent": "781",
                "text": "Incluso dentro del\nmismo individuo",
                "guid": "",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "785",
        "parent": "0",
        "text": "# Miastenia gravis en\n2025 (continuación)",
        "guid": "GFLlBVfrwbZvIMnwcXksiw",
        "children": []
      },
      {
        "id": "786",
        "parent": "0",
        "text": "Anticuerpos AChR",
        "guid": "",
        "children": [
          {
            "id": "787",
            "parent": "786",
            "text": "Clon de anticuerpos con\nentidades principalmente IgG1",
            "guid": "",
            "children": [
              {
                "id": "788",
                "parent": "787",
                "text": "Capacidad de activar\ncomplemento",
                "guid": "",
                "children": []
              },
              {
                "id": "789",
                "parent": "787",
                "text": "Internalización de AChRs",
                "guid": "",
                "children": []
              },
              {
                "id": "790",
                "parent": "787",
                "text": "Causa bloqueo\nde receptores",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "791",
            "parent": "786",
            "text": "Activación del complemento mejorada\npor anticuerpos múltiples",
            "guid": "",
            "children": [
              {
                "id": "792",
                "parent": "791",
                "text": "Dirigidos a diferentes\nepítopos AChR",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "793",
            "parent": "786",
            "text": "Importancia de calidad vs.\ncantidad de anticuerpos",
            "guid": "",
            "children": [
              {
                "id": "794",
                "parent": "793",
                "text": "Determinación de\npatogenicidad",
                "guid": "",
                "children": []
              },
              {
                "id": "795",
                "parent": "793",
                "text": "Politerapia necesaria para frenar variedad\nde acciones patofisiológicas",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "796",
            "parent": "786",
            "text": "Disminución de AChR-Abs después de\ntratamiento con Rituximab",
            "guid": "",
            "children": [
              {
                "id": "797",
                "parent": "796",
                "text": "Niveles no\npredictivos de\nrecaída",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "798",
            "parent": "786",
            "text": "Persistencia de clones de células B\nderivados del timo post-timectomía",
            "guid": "",
            "children": [
              {
                "id": "799",
                "parent": "798",
                "text": "Indicador de\nrespuesta\ndeficiente",
                "guid": "",
                "children": []
              },
              {
                "id": "800",
                "parent": "798",
                "text": "En algunos pacientes paralela a\npersistencia de títulos AChR-Ab",
                "guid": "",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "801",
        "parent": "0",
        "text": "Rol del\ncomplemento en\nAChR-MG",
        "guid": "",
        "children": [
          {
            "id": "802",
            "parent": "801",
            "text": "Interés debido a rol largo\ntiempo reconocido",
            "guid": "",
            "children": []
          },
          {
            "id": "803",
            "parent": "801",
            "text": "Aumento con terapias\ninhibidoras de C5",
            "guid": "",
            "children": []
          },
          {
            "id": "804",
            "parent": "801",
            "text": "Componentes escindidos de\ncascada de complemento",
            "guid": "",
            "children": [
              {
                "id": "805",
                "parent": "804",
                "text": "Clásica y alternativa",
                "guid": "",
                "children": []
              },
              {
                "id": "806",
                "parent": "804",
                "text": "Más abundantes en muestras de pacientes\nAChR-MG recién diagnosticados",
                "guid": "",
                "children": []
              },
              {
                "id": "807",
                "parent": "804",
                "text": "Comparados con\ncontroles sanos",
                "guid": "",
                "children": []
              },
              {
                "id": "808",
                "parent": "804",
                "text": "No disminuidos tras terapia\ninmunosupresora establecida",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "809",
            "parent": "801",
            "text": "Ensayos funcionales\nde complemento",
            "guid": "",
            "children": [
              {
                "id": "810",
                "parent": "809",
                "text": "Sin diferencias entre\npacientes y controles",
                "guid": "",
                "children": []
              },
              {
                "id": "811",
                "parent": "809",
                "text": "Nuevo ensayo capturando ataque de\nmembrana (actividad MAC)",
                "guid": "",
                "children": [
                  {
                    "id": "812",
                    "parent": "811",
                    "text": "Promesa como biomarcador de\nactividad y respuesta a terapia\nanti-complemento",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "813",
            "parent": "801",
            "text": "IL6 bajo investigación como\nbiomarcador potencial",
            "guid": "",
            "children": [
              {
                "id": "814",
                "parent": "813",
                "text": "Bloqueo de receptor evaluado en\nMG (ensayo Satralizumab)",
                "guid": "",
                "children": []
              },
              {
                "id": "815",
                "parent": "813",
                "text": "Ensayo detenido (Tabla 1)",
                "guid": "",
                "children": []
              },
              {
                "id": "816",
                "parent": "813",
                "text": "Estudio transversal: IL6 elevado en\n93 pacientes AChR-MG",
                "guid": "",
                "children": []
              },
              {
                "id": "817",
                "parent": "813",
                "text": "Correlación débil con\nestado MGFA",
                "guid": "",
                "children": []
              },
              {
                "id": "818",
                "parent": "813",
                "text": "Beneficios de Tocilizumab\n(anti-IL6) reportados en casos y\nestudios observacionales",
                "guid": "",
                "children": []
              },
              {
                "id": "819",
                "parent": "813",
                "text": "IL6 y receptor soluble incluidos en panel\ndetallado de biomarcadores",
                "guid": "",
                "children": [
                  {
                    "id": "820",
                    "parent": "819",
                    "text": "Anunciado en trastorno del espectro\nde neuromielitis óptica tratado con\ninhibidor de receptor IL6",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "id": "821",
        "parent": "0",
        "text": "No olvides las células T",
        "guid": "",
        "children": [
          {
            "id": "822",
            "parent": "821",
            "text": "Células T CD4+ como socios críticos\nen procesos de células B",
            "guid": "",
            "children": [
              {
                "id": "823",
                "parent": "822",
                "text": "Relevantes para\nautoinmunidad",
                "guid": "",
                "children": []
              },
              {
                "id": "824",
                "parent": "822",
                "text": "Cambio de clase",
                "guid": "",
                "children": []
              },
              {
                "id": "825",
                "parent": "822",
                "text": "Hipermutación somática",
                "guid": "",
                "children": []
              },
              {
                "id": "826",
                "parent": "822",
                "text": "Maduración",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "827",
            "parent": "821",
            "text": "\"T\" en células T\nrepresenta el timo",
            "guid": "",
            "children": [
              {
                "id": "828",
                "parent": "827",
                "text": "Órgano crítico para\ndesarrollo y educación",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "829",
            "parent": "821",
            "text": "Población de dos\nfenotipos CD4+ T",
            "guid": "",
            "children": [
              {
                "id": "830",
                "parent": "829",
                "text": "TH17TEFF (población\nsecretora de TNFα)",
                "guid": "",
                "children": []
              },
              {
                "id": "831",
                "parent": "829",
                "text": "THGM (producen factor estimulante de\ncolonias granulocito-monocito)",
                "guid": "",
                "children": []
              },
              {
                "id": "832",
                "parent": "829",
                "text": "Pro-inflamatorios",
                "guid": "",
                "children": []
              },
              {
                "id": "833",
                "parent": "829",
                "text": "Secuestrados en timo",
                "guid": "",
                "children": []
              },
              {
                "id": "834",
                "parent": "829",
                "text": "Reducidos en circulación\nperiférica de pacientes MG",
                "guid": "",
                "children": []
              },
              {
                "id": "835",
                "parent": "829",
                "text": "Correlación inversa con\nseveridad de enfermedad",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "836",
            "parent": "821",
            "text": "Timectomía parece liberar estas\ncélulas a circulación periférica",
            "guid": "",
            "children": []
          },
          {
            "id": "837",
            "parent": "821",
            "text": "TDCTDM propuesto como\nbiomarcador de enfermedad",
            "guid": "",
            "children": []
          },
          {
            "id": "838",
            "parent": "821",
            "text": "Otro estudio concluyó",
            "guid": "",
            "children": [
              {
                "id": "839",
                "parent": "838",
                "text": "Subconjunto CD4+ T con IL17-positivo\ny T folicular helper (TFH7+)",
                "guid": "",
                "children": []
              },
              {
                "id": "840",
                "parent": "838",
                "text": "Disminución más sensible que\nplasmablastos post-inmunoterapia",
                "guid": "",
                "children": []
              },
              {
                "id": "841",
                "parent": "838",
                "text": "Mayor proporción de TFH7+ células\nasociada con QMG mayor",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "842",
            "parent": "821",
            "text": "Citoquina T cell, entre otras\nincluyendo aumento en GM-CSF",
            "guid": "",
            "children": [
              {
                "id": "843",
                "parent": "842",
                "text": "Apoyo de resultados de otros\ninvestigadores en MG",
                "guid": "",
                "children": []
              },
              {
                "id": "844",
                "parent": "842",
                "text": "Potencial marcador de crisis y actividad\nlongitudinal de enfermedad",
                "guid": "",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "845",
        "parent": "0",
        "text": "Conclusión: guías y biomarcadores\nreaccionan a nuevas terapias",
        "guid": "",
        "children": [
          {
            "id": "846",
            "parent": "845",
            "text": "Guías comenzando a\nincorporar nuevos tratamientos",
            "guid": "",
            "children": []
          },
          {
            "id": "847",
            "parent": "845",
            "text": "Biomarcadores pueden ayudar a\nrefinar práctica clínica",
            "guid": "",
            "children": []
          },
          {
            "id": "848",
            "parent": "845",
            "text": "Respuesta al tratamiento y biomarcadores\ndifieren entre AChR y MuSK-MG",
            "guid": "",
            "children": [
              {
                "id": "849",
                "parent": "848",
                "text": "Reflejo de diferentes\nmecanismos de enfermedad",
                "guid": "",
                "children": []
              },
              {
                "id": "850",
                "parent": "848",
                "text": "Predominancia de\nsubclase IgG",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "851",
            "parent": "845",
            "text": "Otros factores influyentes\npara práctica clínica",
            "guid": "",
            "children": [
              {
                "id": "852",
                "parent": "851",
                "text": "\"Edad\" y \"etapa\" de MG",
                "guid": "",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "853",
        "parent": "0",
        "text": "Miastenia gravis: no solo\n\"edad\" sino también \"etapa\"",
        "guid": "",
        "children": [
          {
            "id": "854",
            "parent": "853",
            "text": "Revisión previa destacó\nincidencia creciente de LOMG",
            "guid": "",
            "children": [
              {
                "id": "855",
                "parent": "854",
                "text": "Fenómeno epidemiológico\nobservado y discutido",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "856",
            "parent": "853",
            "text": "Estudio epidemiológico prospectivo\ndel Reino Unido (2014-2018)",
            "guid": "",
            "children": [
              {
                "id": "857",
                "parent": "856",
                "text": "Incidencia más alta de nueva\nMG en grupo >65 años",
                "guid": "",
                "children": [
                  {
                    "id": "858",
                    "parent": "857",
                    "text": "51.3/1,000,000\npara hombres",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "859",
                    "parent": "857",
                    "text": "51.3/1,000,000\npara mujeres",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "860",
                "parent": "856",
                "text": "Comparado con 17.6/1,000,000\nen población general",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "861",
            "parent": "853",
            "text": "Grupo >65 único con aumento de\nincidencia durante período investigado",
            "guid": "",
            "children": []
          },
          {
            "id": "862",
            "parent": "853",
            "text": "Hallazgos confirmados\nen estudios de:",
            "guid": "",
            "children": [
              {
                "id": "863",
                "parent": "862",
                "text": "Norte de Europa",
                "guid": "",
                "children": []
              },
              {
                "id": "864",
                "parent": "862",
                "text": "Japón",
                "guid": "",
                "children": []
              },
              {
                "id": "865",
                "parent": "862",
                "text": "Alemania",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "866",
            "parent": "853",
            "text": "Prevalencia duplicada en\nJapón (2006-2017)",
            "guid": "",
            "children": []
          },
          {
            "id": "867",
            "parent": "853",
            "text": "Estudio alemán: prevalencia\nmás alta en >80 años",
            "guid": "",
            "children": []
          },
          {
            "id": "868",
            "parent": "853",
            "text": "LOMG capturada en\ncohortes más recientes",
            "guid": "",
            "children": []
          },
          {
            "id": "869",
            "parent": "853",
            "text": "Importante recordar",
            "guid": "",
            "children": [
              {
                "id": "870",
                "parent": "869",
                "text": "Grupos de edad media y superior en\nestudios de prevalencia",
                "guid": "",
                "children": []
              },
              {
                "id": "871",
                "parent": "869",
                "text": "Reflejan pacientes con EOMG y\nenfermedad de larga duración",
                "guid": "",
                "children": []
              },
              {
                "id": "872",
                "parent": "869",
                "text": "Especialmente desde\ncuidados intensivos",
                "guid": "",
                "children": []
              },
              {
                "id": "873",
                "parent": "869",
                "text": "Tasas de\nsupervivencia MG\nmejoradas",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "874",
            "parent": "853",
            "text": "Estudios no muestran mortalidad aumentada\ncomparada con población general",
            "guid": "",
            "children": []
          },
          {
            "id": "875",
            "parent": "853",
            "text": "Informes variables sobre curso de\nenfermedad y probabilidad de remisión",
            "guid": "",
            "children": [
              {
                "id": "876",
                "parent": "875",
                "text": "EOMG vs. LOMG",
                "guid": "",
                "children": []
              },
              {
                "id": "877",
                "parent": "875",
                "text": "Estudios reportan\nresultados comparables",
                "guid": "",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "878",
        "parent": "0",
        "text": "# Miastenia gravis en\n2025 (continuación)",
        "guid": "OzjR1jCqxZJ_UAtZLKeD4w",
        "children": []
      },
      {
        "id": "879",
        "parent": "0",
        "text": "Fig. 5: Cambio en el inicio de Miastenia Gravis\nde inicio tardío (LOMG) y Miastenia Gravis de\ninicio temprano (EOMG)",
        "guid": "",
        "children": [
          {
            "id": "880",
            "parent": "879",
            "text": "Irlanda del Norte\n1990-2008",
            "guid": "",
            "children": []
          },
          {
            "id": "881",
            "parent": "879",
            "text": "IR mostrada en casos por\nmillón persona-años",
            "guid": "",
            "children": []
          },
          {
            "id": "882",
            "parent": "879",
            "text": "Barras de error\nrepresentan IC 95%",
            "guid": "",
            "children": []
          },
          {
            "id": "883",
            "parent": "879",
            "text": "Aumento casi séptuple\nen IR de LOMG",
            "guid": "",
            "children": []
          },
          {
            "id": "884",
            "parent": "879",
            "text": "Aumento de cinco veces en\nIR absoluta de EOMG",
            "guid": "",
            "children": []
          },
          {
            "id": "885",
            "parent": "879",
            "text": "Intervalos de\nconfianza se\nsolapan",
            "guid": "",
            "children": []
          },
          {
            "id": "886",
            "parent": "879",
            "text": "Valores de IR:",
            "guid": "",
            "children": [
              {
                "id": "887",
                "parent": "886",
                "text": "1990-1994: LOMG 5.7 (3.2, 10.\n3) | EOMG 1.5 (0.8, 2.7)",
                "guid": "",
                "children": []
              },
              {
                "id": "888",
                "parent": "886",
                "text": "1995-1999: LOMG 18.3 (13.1, 25.\n6) | EOMG 2.9 (1.3, 3.7)",
                "guid": "",
                "children": []
              },
              {
                "id": "889",
                "parent": "886",
                "text": "2000-2004: LOMG 29.7 (22.8, 38.\n6) | EOMG 2.7 (1.3, 3.7)",
                "guid": "",
                "children": []
              },
              {
                "id": "890",
                "parent": "886",
                "text": "2005-2008: LOMG 39.8 (30.6, 51.\n7) | EOMG 3.1 (1.8, 5.3)",
                "guid": "",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "891",
        "parent": "0",
        "text": "Pronóstico en\npacientes mayores",
        "guid": "",
        "children": [
          {
            "id": "892",
            "parent": "891",
            "text": "Datos longitudinales\nsugieren síntesis",
            "guid": "",
            "children": []
          },
          {
            "id": "893",
            "parent": "891",
            "text": "Aunque puede haber inicio más\nsevero en MG de inicio tardío",
            "guid": "",
            "children": []
          },
          {
            "id": "894",
            "parent": "891",
            "text": "Altamente\nresponsiva al\ntratamiento",
            "guid": "",
            "children": []
          }
        ]
      },
      {
        "id": "895",
        "parent": "0",
        "text": "Etapas de enfermedad",
        "guid": "",
        "children": [
          {
            "id": "896",
            "parent": "895",
            "text": "Cohortes\nhistóricas y\nrecientes",
            "guid": "",
            "children": []
          },
          {
            "id": "897",
            "parent": "895",
            "text": "Curso de enfermedad típicamente en su\nnadir con crisis en primeros años",
            "guid": "",
            "children": []
          },
          {
            "id": "898",
            "parent": "895",
            "text": "Dentro de dos a tres años en estudios\nincluyendo presentaciones pre-siglo XXI",
            "guid": "",
            "children": []
          },
          {
            "id": "899",
            "parent": "895",
            "text": "Después del\ncambio de siglo",
            "guid": "",
            "children": [
              {
                "id": "900",
                "parent": "899",
                "text": "Fase severa puede\ncomprimirse en un solo año",
                "guid": "",
                "children": []
              },
              {
                "id": "901",
                "parent": "899",
                "text": "Beneficio terapéutico en\nprimeros dos años",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "902",
            "parent": "895",
            "text": "Características conocidas de enfermedad\naplicadas a principios de tratamiento",
            "guid": "",
            "children": [
              {
                "id": "903",
                "parent": "902",
                "text": "Pacientes recién\ndiagnosticados en era\nactual",
                "guid": "",
                "children": []
              },
              {
                "id": "904",
                "parent": "902",
                "text": "Disponibilidad de\ninmunoterapias nuevas y\nfuturas",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "905",
            "parent": "895",
            "text": "Incluso en\ncohortes\nmodernas",
            "guid": "",
            "children": [
              {
                "id": "906",
                "parent": "905",
                "text": "5-20% de pacientes permanecen\nrefractarios tras fase explosiva inicial",
                "guid": "",
                "children": []
              },
              {
                "id": "907",
                "parent": "905",
                "text": "Continúan\nexperimentando\nexacerbaciones",
                "guid": "",
                "children": []
              },
              {
                "id": "908",
                "parent": "905",
                "text": "Alta tasa de comorbilidades\ncontribuye a hospitalizaciones",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "909",
            "parent": "895",
            "text": "Factores asociados con\nestatus refractario",
            "guid": "",
            "children": [
              {
                "id": "910",
                "parent": "909",
                "text": "Presencia de timoma",
                "guid": "",
                "children": []
              },
              {
                "id": "911",
                "parent": "909",
                "text": "Estado seronegativo",
                "guid": "",
                "children": []
              },
              {
                "id": "912",
                "parent": "909",
                "text": "Comorbilidades",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "913",
            "parent": "895",
            "text": "Comorbilidades pueden ser resultado de\nregímenes de medicamentos",
            "guid": "",
            "children": []
          },
          {
            "id": "914",
            "parent": "895",
            "text": "Nueva tecnología digital",
            "guid": "",
            "children": [
              {
                "id": "915",
                "parent": "914",
                "text": "Oportunidad para\nnuevos conocimientos",
                "guid": "",
                "children": []
              },
              {
                "id": "916",
                "parent": "914",
                "text": "Cohortes grandes sobre\nevolución longitudinal",
                "guid": "",
                "children": []
              },
              {
                "id": "917",
                "parent": "914",
                "text": "Impacto de enfermedad",
                "guid": "",
                "children": [
                  {
                    "id": "918",
                    "parent": "917",
                    "text": "Fatiga",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "919",
                    "parent": "917",
                    "text": "Historia ocupacional",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "920",
                    "parent": "917",
                    "text": "Calidad de vida",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "921",
                    "parent": "917",
                    "text": "Carga del cuidador",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "id": "922",
        "parent": "0",
        "text": "Comorbilidades y\npacientes mayores",
        "guid": "",
        "children": [
          {
            "id": "923",
            "parent": "922",
            "text": "Tema emergente en contexto de cambio\nde estilos de vida y demografía",
            "guid": "",
            "children": []
          },
          {
            "id": "924",
            "parent": "922",
            "text": "Comorbilidades prevalentes en\ntasas similares y altas en\npoblaciones occidentales",
            "guid": "",
            "children": []
          },
          {
            "id": "925",
            "parent": "922",
            "text": "Comunes en inicio temprano\ny tardío de miastenia",
            "guid": "",
            "children": []
          },
          {
            "id": "926",
            "parent": "922",
            "text": "Comorbilidades\ncomúnmente\nencontradas",
            "guid": "",
            "children": [
              {
                "id": "927",
                "parent": "926",
                "text": "Hipertensión",
                "guid": "",
                "children": []
              },
              {
                "id": "928",
                "parent": "926",
                "text": "Colesterol alto",
                "guid": "",
                "children": []
              },
              {
                "id": "929",
                "parent": "926",
                "text": "Diabetes",
                "guid": "",
                "children": []
              },
              {
                "id": "930",
                "parent": "926",
                "text": "Cataratas",
                "guid": "",
                "children": []
              },
              {
                "id": "931",
                "parent": "926",
                "text": "Problemas de próstata",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "932",
            "parent": "922",
            "text": "Polifarmacia para condiciones\ncoexistentes común",
            "guid": "",
            "children": []
          },
          {
            "id": "933",
            "parent": "922",
            "text": "Requieren manejo cuidadoso junto\ncon tratamiento de miastenia",
            "guid": "",
            "children": []
          },
          {
            "id": "934",
            "parent": "922",
            "text": "Estudio\ncaso-control\ndanés",
            "guid": "",
            "children": [
              {
                "id": "935",
                "parent": "934",
                "text": "No identificó riesgo aumentado de\nfracturas osteoporóticas en pacientes\nMG con terapia de esteroides",
                "guid": "",
                "children": []
              },
              {
                "id": "936",
                "parent": "934",
                "text": "Atribuido a adecuada\nprotección ósea",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "937",
            "parent": "922",
            "text": "Efectos secundarios\nrelacionados con tratamiento",
            "guid": "",
            "children": [
              {
                "id": "938",
                "parent": "937",
                "text": "Infección fatal reportada con\ninmunoterapia en poblaciones mayores",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "939",
            "parent": "922",
            "text": "Peores resultados en personas\nmayores vinculados a reticencia a\ninmunoterapia más agresiva",
            "guid": "",
            "children": []
          },
          {
            "id": "940",
            "parent": "922",
            "text": "Serie de casos de siete\npacientes LOMG ≥55 años",
            "guid": "",
            "children": [
              {
                "id": "941",
                "parent": "940",
                "text": "Eficacia y tolerabilidad\nalentadoras de Rituximab",
                "guid": "",
                "children": []
              },
              {
                "id": "942",
                "parent": "940",
                "text": "Argumenta por uso potencial más\ntemprano en pacientes mayores",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "943",
            "parent": "922",
            "text": "Terapia de mantenimiento suave\npuede tener perfil preferencial de\nefectos secundarios",
            "guid": "",
            "children": []
          }
        ]
      },
      {
        "id": "944",
        "parent": "0",
        "text": "# Miastenia gravis en\n2025 (continuación)",
        "guid": "UcOfHXb4N0wleAKCHf61UA",
        "children": []
      },
      {
        "id": "945",
        "parent": "0",
        "text": "Evolución en pruebas\nde diagnóstico",
        "guid": "",
        "children": [
          {
            "id": "946",
            "parent": "945",
            "text": "Antibody\nseronegatividad por\nRIA",
            "guid": "",
            "children": [
              {
                "id": "947",
                "parent": "946",
                "text": "Considerado el estándar oro para\ndetección de anticuerpos AChR",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "948",
            "parent": "945",
            "text": "CBAs comerciales generados de\nmanera similar a CBA vivo",
            "guid": "",
            "children": [
              {
                "id": "949",
                "parent": "948",
                "text": "Sustrato fijado para permitir\nvida útil más larga",
                "guid": "",
                "children": []
              },
              {
                "id": "950",
                "parent": "948",
                "text": "No tan precisos\ncomo prueba viva",
                "guid": "",
                "children": []
              },
              {
                "id": "951",
                "parent": "948",
                "text": "Adición de amplificación de\nfluorescencia ha mejorado sensibilidad",
                "guid": "",
                "children": []
              },
              {
                "id": "952",
                "parent": "948",
                "text": "CBA fijo comercial de China mejoró\n12% sobre RIA o ELISA",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "953",
            "parent": "945",
            "text": "Pequeña proporción de MG\nsigue siendo negativa",
            "guid": "",
            "children": [
              {
                "id": "954",
                "parent": "953",
                "text": "24% por CBA fijo\npositivo por RIA",
                "guid": "",
                "children": []
              },
              {
                "id": "955",
                "parent": "953",
                "text": "25% por ELISA",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "956",
            "parent": "945",
            "text": "Estudios similares con\nCBAs vivos necesarios",
            "guid": "",
            "children": []
          },
          {
            "id": "957",
            "parent": "945",
            "text": "RIA superado por ensayos basados en\ncélulas para detección de AChR-IgG",
            "guid": "",
            "children": []
          }
        ]
      },
      {
        "id": "958",
        "parent": "0",
        "text": "Tiempos de\nprueba en MuSK",
        "guid": "",
        "children": [
          {
            "id": "959",
            "parent": "958",
            "text": "Anticuerpos MuSK\nidentificados por primera vez",
            "guid": "",
            "children": [
              {
                "id": "960",
                "parent": "959",
                "text": "Unión a células COS7\ntransfectadas con MuSK de rata",
                "guid": "",
                "children": []
              },
              {
                "id": "961",
                "parent": "959",
                "text": "ELISA en dominios extracelulares\npurificados de MuSK de rata",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "962",
            "parent": "958",
            "text": "Radioinmunoensayo\ncomercial desarrollado",
            "guid": "",
            "children": [
              {
                "id": "963",
                "parent": "962",
                "text": "Usando dominios extracelulares de\nMuSK de rata o humano",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "964",
            "parent": "958",
            "text": "Una década después: desarrollo de\nCBAs internos y comerciales",
            "guid": "",
            "children": []
          },
          {
            "id": "965",
            "parent": "958",
            "text": "Estudios comparativos\nrecientes sugieren",
            "guid": "",
            "children": [
              {
                "id": "966",
                "parent": "965",
                "text": "ELISA y CBA fijo comercial\naparentemente equivalentes",
                "guid": "",
                "children": []
              },
              {
                "id": "967",
                "parent": "965",
                "text": "No 100% concordantes",
                "guid": "",
                "children": []
              },
              {
                "id": "968",
                "parent": "965",
                "text": "Casos perdidos en cada\nprueba a través de estudios",
                "guid": "",
                "children": []
              },
              {
                "id": "969",
                "parent": "965",
                "text": "CBA interno apareció\nmarginalmente superior a RIA y\nELISA",
                "guid": "",
                "children": []
              },
              {
                "id": "970",
                "parent": "965",
                "text": "Falta de concordancia entre\ntres sistemas persiste",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "971",
            "parent": "958",
            "text": "De 63 individuos\nMuSK-positivos",
            "guid": "",
            "children": [
              {
                "id": "972",
                "parent": "971",
                "text": "47 concordantes",
                "guid": "",
                "children": []
              },
              {
                "id": "973",
                "parent": "971",
                "text": "CBA interno identificó 12\npositivos únicos",
                "guid": "",
                "children": []
              },
              {
                "id": "974",
                "parent": "971",
                "text": "RIA identificó 4\nmuestras únicas",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "975",
            "parent": "958",
            "text": "No todos los ensayos\nvivos son equivalentes",
            "guid": "",
            "children": [
              {
                "id": "976",
                "parent": "975",
                "text": "Células Hep-2 M4\ntransfectadas con MuSK\nhumano",
                "guid": "",
                "children": []
              },
              {
                "id": "977",
                "parent": "975",
                "text": "25/34 MuSK-positivos por\nmuestra viva identificados",
                "guid": "",
                "children": []
              },
              {
                "id": "978",
                "parent": "975",
                "text": "Elección de célula y método de\nexpresión pueden crear diferencia",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "979",
            "parent": "958",
            "text": "Cuando sustrato fue células HEK\ntransfectadas con MuSK humano completo",
            "guid": "",
            "children": [
              {
                "id": "980",
                "parent": "979",
                "text": "32 pacientes MuSK-positivos\nadicionales identificados",
                "guid": "",
                "children": []
              },
              {
                "id": "981",
                "parent": "979",
                "text": "136 RIA-positivos en\nestos estudios",
                "guid": "",
                "children": []
              },
              {
                "id": "982",
                "parent": "979",
                "text": "Aumento de 24% en sens",
                "guid": "",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "983",
        "parent": "0",
        "text": "# Miastenia gravis en\n2025 (continuación)",
        "guid": "TCkIXwX5DlJWgEGCA7rtMA",
        "children": []
      },
      {
        "id": "984",
        "parent": "0",
        "text": "Efectos en\npacientes\nmayores",
        "guid": "",
        "children": [
          {
            "id": "985",
            "parent": "984",
            "text": "Perfil de efectos secundarios de\nterapia de inducción de alta dosis\nen este grupo etario",
            "guid": "",
            "children": []
          }
        ]
      },
      {
        "id": "986",
        "parent": "0",
        "text": "Conclusión: edad y etapa relevantes\nen manejo de miastenia",
        "guid": "",
        "children": [
          {
            "id": "987",
            "parent": "986",
            "text": "Resumen de epidemiología y\nconceptos emergentes de\ninmunoterapia en pacientes mayores",
            "guid": "",
            "children": []
          },
          {
            "id": "988",
            "parent": "986",
            "text": "Avance de protocolos de\ntratamiento basados en evidencia",
            "guid": "",
            "children": []
          },
          {
            "id": "989",
            "parent": "986",
            "text": "Representa una de las \"cuatro\nesperanzas para el futuro\"",
            "guid": "",
            "children": [
              {
                "id": "990",
                "parent": "989",
                "text": "Mejora en diagnóstico",
                "guid": "",
                "children": []
              },
              {
                "id": "991",
                "parent": "989",
                "text": "Pronóstico",
                "guid": "",
                "children": []
              },
              {
                "id": "992",
                "parent": "989",
                "text": "Tratamiento en\ncomunidad de\nmiastenia",
                "guid": "",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "993",
        "parent": "0",
        "text": "Esperanza 1: Progreso en pruebas de\nlaboratorio para diagnóstico rápido y\nserología más sensible",
        "guid": "",
        "children": [
          {
            "id": "994",
            "parent": "993",
            "text": "AChR: de radioinmuno a\nensayos basados en células",
            "guid": "",
            "children": [
              {
                "id": "995",
                "parent": "994",
                "text": "Neurotoxina α-bungarotoxina\n(serpiente Bungarus multicinctus)",
                "guid": "",
                "children": [
                  {
                    "id": "996",
                    "parent": "995",
                    "text": "Central para desarrollo de ensayos\nde autoanticuerpos AChR",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "997",
                    "parent": "995",
                    "text": "Une isoformas adulta y fetal del\nreceptor nicotínico de acetilcolina",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "998",
                    "parent": "995",
                    "text": "Alta afinidad (nM a pM)",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "999",
                    "parent": "995",
                    "text": "Cuando se marca con 125I, crea\nobjetivo específico y estable",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1000",
                    "parent": "995",
                    "text": "Usado durante décadas en laboratorios\nde inmunología diagnóstica",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "1001",
                "parent": "994",
                "text": "Ensayo inmunoabsorbente\nligado a enzimas (ELISA)",
                "guid": "",
                "children": [
                  {
                    "id": "1002",
                    "parent": "1001",
                    "text": "Utilizado por más\nde 40 años",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1003",
                    "parent": "1001",
                    "text": "Sin mejoras sobre\nexactitud de prueba RIA",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1004",
                    "parent": "1001",
                    "text": "Proporción de personas con MG\ngeneralizada idéntica clínicamente",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1005",
                    "parent": "1001",
                    "text": "Características electrofisiológicas a\npacientes seropositivos AChR",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1006",
                    "parent": "1001",
                    "text": "Permanecieron\nseronegativos",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "1007",
                "parent": "994",
                "text": "Resolución de\ndiscordancia",
                "guid": "",
                "children": [
                  {
                    "id": "1008",
                    "parent": "1007",
                    "text": "Transfección transitoria de células\nHEK293T con subunidades AChR",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1009",
                    "parent": "1007",
                    "text": "Adición de rapsina\nagrupadora AChR",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1010",
                    "parent": "1007",
                    "text": "Sustrato de prueba más reflectivo del\nobjetivo de anticuerpos in vivo",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1011",
                    "parent": "1007",
                    "text": "Ensayo basado en\ncélulas agrupadas",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1012",
                    "parent": "1007",
                    "text": "Identificó proporción de pacientes\n\"seronegativos\" como seropositivos",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "1013",
                "parent": "994",
                "text": "Ensayo de células\nvivas (CBA)",
                "guid": "",
                "children": [
                  {
                    "id": "1014",
                    "parent": "1013",
                    "text": "AChRs humanos\nsobreexpresados en células\nvivas",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1015",
                    "parent": "1013",
                    "text": "Presencia de rapsina\nmarcada con fluorescencia",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1016",
                    "parent": "1013",
                    "text": "Agrupa AChRs en puntos",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1017",
                    "parent": "1013",
                    "text": "Suero de paciente incubado con\ncélulas a temperatura ambiente",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1018",
                    "parent": "1013",
                    "text": "Unión AChR identificada con\nanticuerpo secundario fluorescente",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1019",
                    "parent": "1013",
                    "text": "En tres estudios\ncomparativos",
                    "guid": "",
                    "children": [
                      {
                        "id": "1020",
                        "parent": "1019",
                        "text": "Identificó 50 nuevos\ncasos seropositivos",
                        "guid": "",
                        "children": []
                      },
                      {
                        "id": "1021",
                        "parent": "1019",
                        "text": "18-38% de pacientes en estos cohortes\ndefinidos como seronegativos por RIA",
                        "guid": "",
                        "children": []
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "id": "1022",
        "parent": "0",
        "text": "Fig. 6: Ensayos basados en\ncélulas en miastenia gravis",
        "guid": "",
        "children": [
          {
            "id": "1023",
            "parent": "1022",
            "text": "Ensayos basados en células\nvivas: método más sensible para\ndetectar anticuerpos",
            "guid": "",
            "children": []
          },
          {
            "id": "1024",
            "parent": "1022",
            "text": "A: Células HEK transfectadas\ncon subunidades α, β, y δ AChR\ncon subunidad ε o γ",
            "guid": "",
            "children": [
              {
                "id": "1025",
                "parent": "1024",
                "text": "Rapsina-eGFP etiquetada es\nsustrato para ensayo de\nanticuerpos AChR agrupados",
                "guid": "",
                "children": []
              },
              {
                "id": "1026",
                "parent": "1024",
                "text": "AChR mostrados en azul",
                "guid": "",
                "children": []
              },
              {
                "id": "1027",
                "parent": "1024",
                "text": "Anticuerpo de\npaciente en azul\nclaro",
                "guid": "",
                "children": []
              },
              {
                "id": "1028",
                "parent": "1024",
                "text": "Anticuerpo secundario en\nnegro con fluorocromo rojo",
                "guid": "",
                "children": []
              },
              {
                "id": "1029",
                "parent": "1024",
                "text": "Rapsina-eGFP en verde",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "1030",
            "parent": "1022",
            "text": "B: Células HEK transfectadas con MuSK\netiquetado c-terminal con eGFP",
            "guid": "",
            "children": [
              {
                "id": "1031",
                "parent": "1030",
                "text": "Sustrato para ensayo\nMuSK en vivo",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "1032",
            "parent": "1022",
            "text": "C: Ejemplos de resultados",
            "guid": "",
            "children": [
              {
                "id": "1033",
                "parent": "1032",
                "text": "Fila superior: prueba\nanticuerpo AChR positiva",
                "guid": "",
                "children": []
              },
              {
                "id": "1034",
                "parent": "1032",
                "text": "Fila media: prueba\nMuSK positiva",
                "guid": "",
                "children": []
              },
              {
                "id": "1035",
                "parent": "1032",
                "text": "Fila inferior: control negativo\npara anticuerpo AChR",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "1036",
            "parent": "1022",
            "text": "AChR: receptor\nacetilcolina",
            "guid": "",
            "children": []
          },
          {
            "id": "1037",
            "parent": "1022",
            "text": "eGFP: proteína\nfluorescente verde\nmejorada",
            "guid": "",
            "children": []
          },
          {
            "id": "1038",
            "parent": "1022",
            "text": "HEK: riñón\nembrionario\nhumano",
            "guid": "",
            "children": []
          },
          {
            "id": "1039",
            "parent": "1022",
            "text": "IgG: inmunoglobulina G",
            "guid": "",
            "children": []
          },
          {
            "id": "1040",
            "parent": "1022",
            "text": "MuSK: quinasa\nespecífica muscular",
            "guid": "",
            "children": []
          }
        ]
      },
      {
        "id": "1041",
        "parent": "0",
        "text": "# Miastenia gravis en\n2025 (continuación)",
        "guid": "SdKP73L_CZNBaRYffHFtKw",
        "children": []
      },
      {
        "id": "1042",
        "parent": "0",
        "text": "Necesidad de\nregímenes\nadaptados",
        "guid": "",
        "children": [
          {
            "id": "1043",
            "parent": "1042",
            "text": "Estudios sobre regímenes de\ndosificación para adultos mayores",
            "guid": "",
            "children": [
              {
                "id": "1044",
                "parent": "1043",
                "text": "Similar a trabajos\nen vasculitis",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "1045",
            "parent": "1042",
            "text": "Experiencia en\ncentro de Oxford",
            "guid": "",
            "children": [
              {
                "id": "1046",
                "parent": "1045",
                "text": "Rituximab en dosis muy bajas en\npacientes MG mayores",
                "guid": "",
                "children": []
              },
              {
                "id": "1047",
                "parent": "1045",
                "text": "Sin historial extenso de\ninmunoterapias",
                "guid": "",
                "children": []
              },
              {
                "id": "1048",
                "parent": "1045",
                "text": "Dosis únicas de 500 mg\no incluso 200 mg",
                "guid": "",
                "children": []
              },
              {
                "id": "1049",
                "parent": "1045",
                "text": "Monitoreo de subconjuntos de\ncélulas B post-tratamiento",
                "guid": "",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "1050",
        "parent": "0",
        "text": "Esperanza 4: El poder de las\ncélulas T: ¿una cura para MG?",
        "guid": "",
        "children": [
          {
            "id": "1051",
            "parent": "1050",
            "text": "Terapia CAR T",
            "guid": "",
            "children": [
              {
                "id": "1052",
                "parent": "1051",
                "text": "Aprovecha poder de células T para\neliminar células específicas",
                "guid": "",
                "children": []
              },
              {
                "id": "1053",
                "parent": "1051",
                "text": "Enfoque básico: infusión de\npacientes con células T autólogas",
                "guid": "",
                "children": []
              },
              {
                "id": "1054",
                "parent": "1051",
                "text": "Bioingeniería de receptores contra\nentidad relevante para enfermedad",
                "guid": "",
                "children": []
              },
              {
                "id": "1055",
                "parent": "1051",
                "text": "Establecida en\nmalignidad\nhematológica",
                "guid": "",
                "children": []
              },
              {
                "id": "1056",
                "parent": "1051",
                "text": "Prometedora en\nenfermedad autoinmune",
                "guid": "",
                "children": [
                  {
                    "id": "1057",
                    "parent": "1056",
                    "text": "Capacidad de\nfocalización precisa",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1058",
                    "parent": "1056",
                    "text": "Penetración de\nnichos inmunes",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "1059",
            "parent": "1050",
            "text": "Mayor estudio\nhasta la fecha",
            "guid": "",
            "children": [
              {
                "id": "1060",
                "parent": "1059",
                "text": "14 pacientes con\nMG generalizada",
                "guid": "",
                "children": [
                  {
                    "id": "1061",
                    "parent": "1060",
                    "text": "AChR o anticuerpos MuSK",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1062",
                    "parent": "1060",
                    "text": "Un seronegativo",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "1063",
                "parent": "1059",
                "text": "Recibieron Descartes-08",
                "guid": "",
                "children": [
                  {
                    "id": "1064",
                    "parent": "1063",
                    "text": "Activo contra antígeno de\nmaduración de células B (BCMA)",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1065",
                    "parent": "1063",
                    "text": "Molécula en\ncélulas\nplasmáticas",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "1066",
                "parent": "1059",
                "text": "Ensayo fase temprana, no\npotenciado para examinar eficacia",
                "guid": "",
                "children": []
              },
              {
                "id": "1067",
                "parent": "1059",
                "text": "Bien tolerado",
                "guid": "",
                "children": [
                  {
                    "id": "1068",
                    "parent": "1067",
                    "text": "Un efecto secundario relacionado con\ntratamiento serio (urticaria)",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1069",
                    "parent": "1067",
                    "text": "Métricas prometedoras sobre\ntrayectoria de enfermedad",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1070",
                    "parent": "1067",
                    "text": "Sin\nhipogammaglobulinemia\nobservada",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "1071",
            "parent": "1050",
            "text": "Informes clínicos a\npequeña escala",
            "guid": "",
            "children": [
              {
                "id": "1072",
                "parent": "1071",
                "text": "Uso de CAR T CD19-dirigido en miastenia\nLambert-Eaton refractaria (LEMS)",
                "guid": "",
                "children": []
              },
              {
                "id": "1073",
                "parent": "1071",
                "text": "Informe de caso único\nen MG AChR+",
                "guid": "",
                "children": [
                  {
                    "id": "1074",
                    "parent": "1073",
                    "text": "Buena respuesta",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "1075",
            "parent": "1050",
            "text": "Basado en\ndatos\npreclínicos",
            "guid": "",
            "children": [
              {
                "id": "1076",
                "parent": "1075",
                "text": "Ensayo fase 1 de CAR T específico\npara MuSK (MuSK-CAART)",
                "guid": "",
                "children": [
                  {
                    "id": "1077",
                    "parent": "1076",
                    "text": "Actualmente reclutando\n(NCT05451212)",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1078",
                    "parent": "1076",
                    "text": "Representa paso adicional de\nmedicina de precisión",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "1079",
            "parent": "1050",
            "text": "Métodos CAR T\nprobablemente se\nexpandirán",
            "guid": "",
            "children": [
              {
                "id": "1080",
                "parent": "1079",
                "text": "Preguntas pendientes",
                "guid": "",
                "children": [
                  {
                    "id": "1081",
                    "parent": "1080",
                    "text": "Costo",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1082",
                    "parent": "1080",
                    "text": "Emergencia potencial de\nefectos secundarios a escala",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "id": "1083",
        "parent": "0",
        "text": "Posdata: ¿Podemos predecir un\ncurso de enfermedad agresivo o\nresponsivo al tratamiento?",
        "guid": "",
        "children": [
          {
            "id": "1084",
            "parent": "1083",
            "text": "Relevancia directa al considerar\nenfoques de alto impacto",
            "guid": "",
            "children": [
              {
                "id": "1085",
                "parent": "1084",
                "text": "Alto esfuerzo",
                "guid": "",
                "children": []
              },
              {
                "id": "1086",
                "parent": "1084",
                "text": "Alto costo",
                "guid": "",
                "children": []
              },
              {
                "id": "1087",
                "parent": "1084",
                "text": "Como terapia CAR T",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "1088",
            "parent": "1083",
            "text": "Alta relevancia clínica y\nutilidad para predecir",
            "guid": "",
            "children": [
              {
                "id": "1089",
                "parent": "1088",
                "text": "Qué pacientes desarrollarán\nenfermedad agresiva",
                "guid": "",
                "children": []
              },
              {
                "id": "1090",
                "parent": "1088",
                "text": "Capacidad de lograr selección precisa\nde tratamientos racionales",
                "guid": "",
                "children": []
              },
              {
                "id": "1091",
                "parent": "1088",
                "text": "Terapias adaptadas\nindividualmente",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "1092",
            "parent": "1083",
            "text": "Biomarcadores\nexploratorios en fase\ntemprana",
            "guid": "",
            "children": [
              {
                "id": "1093",
                "parent": "1092",
                "text": "Esperan traducción a herramientas\nclínicamente relevantes",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "1094",
            "parent": "1083",
            "text": "Avenida prometedora y\npotencialmente muy responsiva",
            "guid": "",
            "children": [
              {
                "id": "1095",
                "parent": "1094",
                "text": "Uso de datos adquiridos vía\nsmartphones de pacientes",
                "guid": "",
                "children": []
              },
              {
                "id": "1096",
                "parent": "1094",
                "text": "Estudio piloto recientemente capaz de\ncuantificar grado de ptosis vía \"selfies\"",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "1097",
            "parent": "1083",
            "text": "Probable combinación de\nbiomarcadores informativos",
            "guid": "",
            "children": [
              {
                "id": "1098",
                "parent": "1097",
                "text": "Para pronóstico, como se\ndemostró en otra enfermedad\nneurológica (esclerosis múltiple)",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "1099",
            "parent": "1083",
            "text": "Aprendizaje automático y informática\nentrando en espacio MG",
            "guid": "",
            "children": [
              {
                "id": "1100",
                "parent": "1099",
                "text": "Actualmente en infancia",
                "guid": "",
                "children": []
              },
              {
                "id": "1101",
                "parent": "1099",
                "text": "Potencial para algoritmos\npredictivos aplicables en futuro",
                "guid": "",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "1102",
        "parent": "0",
        "text": "Recuadro 1: Caso ilustrativo de MG\ngeneralizada AChR-positiva con\nprotección de unión neuromuscular",
        "guid": "",
        "children": [
          {
            "id": "1103",
            "parent": "1102",
            "text": "Paciente: Mujer, 53 años",
            "guid": "",
            "children": []
          },
          {
            "id": "1104",
            "parent": "1102",
            "text": "Datos clínicos:",
            "guid": "",
            "children": [
              {
                "id": "1105",
                "parent": "1104",
                "text": "Inicio a los 25 años",
                "guid": "",
                "children": []
              },
              {
                "id": "1106",
                "parent": "1104",
                "text": "Timectomía a los 28\naños (hiperplasia)",
                "guid": "",
                "children": []
              },
              {
                "id": "1107",
                "parent": "1104",
                "text": "Respuesta incompleta a terapia\nprolongada de esteroides",
                "guid": "",
                "children": []
              },
              {
                "id": "1108",
                "parent": "1104",
                "text": "Agentes inmunosupresores probados\nsustancialmente a lo largo de años",
                "guid": "",
                "children": []
              },
              {
                "id": "1109",
                "parent": "1104",
                "text": "Efectos secundarios significativos\nde terapia con esteroides",
                "guid": "",
                "children": [
                  {
                    "id": "1110",
                    "parent": "1109",
                    "text": "Aumento de peso",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1111",
                    "parent": "1109",
                    "text": "Osteoporosis temprana",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1112",
                    "parent": "1109",
                    "text": "Cataratas tempranas",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1113",
                    "parent": "1109",
                    "text": "Cambios cutáneos",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "1114",
                "parent": "1104",
                "text": "IVIG crónico mensual por más\nde 20 años (hasta 2021)",
                "guid": "",
                "children": []
              },
              {
                "id": "1115",
                "parent": "1104",
                "text": "Dependiente de respuesta a\nIVIG para funcionamiento",
                "guid": "",
                "children": []
              },
              {
                "id": "1116",
                "parent": "1104",
                "text": "Desde inicio de tratamiento con\ninhibidor del complemento (2021)",
                "guid": "",
                "children": [
                  {
                    "id": "1117",
                    "parent": "1116",
                    "text": "Mejoría progresiva",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1118",
                    "parent": "1116",
                    "text": "Recuperación de fuerza\nmuscular sostenida",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "1119",
                "parent": "1104",
                "text": "Sin manifestaciones\nclínicas de MG por 3 años",
                "guid": "",
                "children": []
              },
              {
                "id": "1120",
                "parent": "1104",
                "text": "Fuera de otros\ntratamientos MG por 2\naños",
                "guid": "",
                "children": []
              },
              {
                "id": "1121",
                "parent": "1104",
                "text": "Regreso a vida normal",
                "guid": "",
                "children": [
                  {
                    "id": "1122",
                    "parent": "1121",
                    "text": "Viajes",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1123",
                    "parent": "1121",
                    "text": "Ocupada con\nactividades\nfamiliares",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1124",
                    "parent": "1121",
                    "text": "Planes para\nvolver a trabajar",
                    "guid": "",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "id": "1125",
        "parent": "0",
        "text": "# Miastenia gravis en\n2025 (continuación)",
        "guid": "",
        "children": []
      },
      {
        "id": "1126",
        "parent": "0",
        "text": "Reconocimientos\ny financiación",
        "guid": "",
        "children": [
          {
            "id": "1127",
            "parent": "1126",
            "text": "Agradecimientos",
            "guid": "",
            "children": [
              {
                "id": "1128",
                "parent": "1127",
                "text": "Dr. Mark Woodhall y Dr. Saif Huda\npor contribuciones a figura 6",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "1129",
            "parent": "1126",
            "text": "Financiación",
            "guid": "",
            "children": [
              {
                "id": "1130",
                "parent": "1129",
                "text": "Sophie NM Binks - Instituto\nNacional para Investigación en\nSalud y Atención (NIHR)",
                "guid": "",
                "children": []
              },
              {
                "id": "1131",
                "parent": "1129",
                "text": "Angela Vincent - regalías por MuSK y\nensayos AChR (expirados)",
                "guid": "",
                "children": []
              },
              {
                "id": "1132",
                "parent": "1129",
                "text": "Patrick Waters - inventor de patentes para\nensayos de anticuerpos y regalías",
                "guid": "",
                "children": [
                  {
                    "id": "1133",
                    "parent": "1132",
                    "text": "Honorarios de Biogen Idec, Mereo\nBiopharma, Retrogenix",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "1134",
                "parent": "1129",
                "text": "Subvenciones de Gullty-Jackson\nCharitable Foundation, Euroimmun AG",
                "guid": "",
                "children": []
              },
              {
                "id": "1135",
                "parent": "1129",
                "text": "Laboratorio de Diagnóstico de\nAutoinmunidad de Oxford",
                "guid": "",
                "children": [
                  {
                    "id": "1136",
                    "parent": "1135",
                    "text": "Servicio de Comisión del\nNHS para NMOSD",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "1137",
                "parent": "1129",
                "text": "M Isabel Leite - NHS, Comisión de\nEspecialistas para Trastornos de Mielina",
                "guid": "",
                "children": [
                  {
                    "id": "1138",
                    "parent": "1137",
                    "text": "Comisión para\nNeuromielitis Óptica",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1139",
                    "parent": "1137",
                    "text": "Universidad de Oxford",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "1140",
                "parent": "1129",
                "text": "Subvenciones de investigación\nde UK y asociaciones para\npacientes con miastenia",
                "guid": "",
                "children": [
                  {
                    "id": "1141",
                    "parent": "1140",
                    "text": "Myaware",
                    "guid": "",
                    "children": []
                  },
                  {
                    "id": "1142",
                    "parent": "1140",
                    "text": "Distrofia Muscular UK",
                    "guid": "",
                    "children": []
                  }
                ]
              },
              {
                "id": "1143",
                "parent": "1129",
                "text": "Honorarios de\nconferencias",
                "guid": "",
                "children": []
              },
              {
                "id": "1144",
                "parent": "1129",
                "text": "Participa en consejos\ncientíficos y educativos",
                "guid": "",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "1145",
        "parent": "0",
        "text": "Disponibilidad de datos",
        "guid": "",
        "children": [
          {
            "id": "1146",
            "parent": "1145",
            "text": "Declaración no apropiada por ser artículo\nde revisión sin datos originales",
            "guid": "",
            "children": []
          }
        ]
      },
      {
        "id": "1147",
        "parent": "0",
        "text": "Declaraciones",
        "guid": "",
        "children": [
          {
            "id": "1148",
            "parent": "1147",
            "text": "Conflicto de interés",
            "guid": "",
            "children": [
              {
                "id": "1149",
                "parent": "1148",
                "text": "IMM y MA sin nada\nque declarar",
                "guid": "",
                "children": []
              }
            ]
          },
          {
            "id": "1150",
            "parent": "1147",
            "text": "Acceso abierto",
            "guid": "",
            "children": [
              {
                "id": "1151",
                "parent": "1150",
                "text": "Licencia Creative Commons\nAttribution 4.0 Internacional",
                "guid": "",
                "children": []
              },
              {
                "id": "1152",
                "parent": "1150",
                "text": "Permite uso,\ncompartir,\nadaptación",
                "guid": "",
                "children": []
              },
              {
                "id": "1153",
                "parent": "1150",
                "text": "Requiere crédito apropiado\na autores originales",
                "guid": "",
                "children": []
              },
              {
                "id": "1154",
                "parent": "1150",
                "text": "Imágenes en Creative Commons,\nexcepto indicación en contrario",
                "guid": "",
                "children": []
              },
              {
                "id": "1155",
                "parent": "1150",
                "text": "Licencia disponible en:\nhttp://creativecommons.\norg/licenses/by/4.0/",
                "guid": "",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "1156",
        "parent": "0",
        "text": "Referencias",
        "guid": "",
        "children": [
          {
            "id": "1157",
            "parent": "1156",
            "text": "1-25. [Lista de referencias bibliográficas académicas\nsobre miastenia gravis, timectomía, tratamientos,\naspectos inmunológicos y epidemiológicos]",
            "guid": "",
            "children": []
          }
        ]
      }
    ]
  },
  "node_count": 1158,
  "relations": [],
  "cross_references": [
    {
      "from_node": "497",
      "reference": "MGTX"
    }
  ],
  "specialty": "General",
  "folder": "- Entidades clínicas/Neurología",
  "filename": "Miastenia ...-2025",
  "id": "map_1620",
  "resolved_references": []
}